



Systemic lupus erythematosus: Diagnosis and clinical management

Andrea Fava, Michelle Petri*

Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA



ARTICLE INFO

Keywords:

Systemic lupus erythematosus
Diagnosis
Management

ABSTRACT

Systemic lupus erythematosus (SLE) is a worldwide chronic autoimmune disease which may affect every organ and tissue. Genetic predisposition, environmental triggers, and the hormonal milieu, interplay in disease development and activity. Clinical manifestations and the pattern of organ involvement are widely heterogeneous, reflecting the complex mosaic of disrupted molecular pathways converging into the SLE clinical phenotype. The SLE complex pathogenesis involves multiple cellular components of the innate and immune systems, presence of autoantibodies and immunocomplexes, engagement of the complement system, dysregulation of several cytokines including type I interferons, and disruption of the clearance of nucleic acids after cell death. Use of immunomodulators and immunosuppression has altered the natural course of SLE. In addition, morbidity and mortality in SLE not only derive from direct immune mediated tissue damage but also from SLE and treatment associated complications such as accelerated coronary artery disease and increased infection risk.

Here, we review the diagnostic approach as well as the etiopathogenetic rationale and clinical evidence for the management of SLE. This includes 1) lifestyle changes such as avoidance of ultraviolet light; 2) prevention of comorbidities including coronary artery disease, osteoporosis, infections, and drug toxicities; 3) use of immunomodulators (i.e. hydroxychloroquine and vitamin D); and 4) immunosuppressants and targeted therapy. We also review new upcoming agents and regimens currently under study.

1. Introduction

Systemic lupus erythematosus (SLE) is the quintessential autoimmune disease. A complex interaction of impaired apoptotic clearance, upregulation of innate and adaptive immune system, complement activation, immune complexes, and tissue inflammation culminates in a self-sustained autoimmune process. Multiple pathogenic mechanisms likely can converge toward the clinical phenotypes that we call SLE. In fact, while many organs and tissues may be affected by SLE, the pattern of clinical manifestations and autoimmune phenomena is heterogeneous among patients and even changes over time in individual patients. For this reason, diagnosis is often difficult or delayed and relies on keen clinical expertise to combine clinical and immunological findings. Here, we review classification criteria and current and future treatments with a mechanistic and evidence-based point of view.

2. Epidemiology

Lupus is a worldwide disease with a striking predilection for women of childbearing age. In women between the age of 15 and 44 years, the female to male ratio is up to 13:1 while it is only 2:1 in children and in

the elderly [1–3]. While present across ethnicities, it is more prevalent in non-Caucasians. While prevalence in Europe and United States is higher in people of African descent, SLE is infrequent in Africa [4,5]. In the United States, it is more common in African-Americans, who also tend to have worse outcomes. In fact, African-American women are about 3 times more likely to have lupus and suffer greater mortality compared to Caucasian-Americans [6]. The Centers for Disease Control and Prevention report an estimated prevalence of about 322,000 cases of probable or definite SLE, higher in African Americans, American Indians and Alaska Natives [3,7–10].

3. Pathogenesis overview

The clinical onset of SLE requires an interaction of genetic predisposition, environmental precipitants, immunological and hormonal factors. In such a permissive environment, along with proinflammatory stimuli such as type 1 interferons and other cytokines, immune tolerance to self-antigens is lost [11]. Autoimmunity then follows driven by a complex interplay of defective clearance of apoptotic waste and immune complexes along with neutrophil extracellular traps, sensing of nucleic acids, disrupted lymphocyte biology, and interferon pathways

* Corresponding author.

E-mail address: mpetri@jhmi.edu (M. Petri).

<https://doi.org/10.1016/j.jaut.2018.11.001>

Received 11 September 2018; Received in revised form 1 November 2018; Accepted 1 November 2018

Available online 16 November 2018

0896-8411/ © 2018 Elsevier Ltd. All rights reserved.

[11].

The genetic susceptibility is suggested by the 11–50% monozygotic twin concordance and increased risk in families [12]. Many genes have been associated with a predisposition to develop lupus, typically encoding for immune components including HLA, IRF5, ITGAM, STAT4, BLK and CTLA4 among others [12,13].

Many environmental triggers have been implicated in lupus. Ultraviolet light (the most recognized), drugs/supplements (echinacea, trimethoprim/sulfamethoxazole) [14–16], smoking [17], infections [18,19] (Epstein-Barr virus in particular [20]), silica [21], mercury [22] and others [19,23,24]. Psychological stress has also been linked to a 50% increase risk of developing lupus [25,26].

In lupus, there is evidence for disruption of both the innate and adaptive arms of the immune system, connected in a feedback loop. T cells are defective and their aberration in lupus is complex [11,27,28]. They fail to produce enough IL-2 and there is a polarization toward Th17 over Tregs. There is an excess of double-negative T lymphocytes. T cells in SLE provide excessive help to B cells. There is evidence of an excess of autoreactive B cells but with overall B cell lymphopenia. The hyperactivation of the BlyS or BAFF pathway, a T cell independent B cell survival pathway, led to the development of a new biologic therapy, as described later.

In addition, the identification of a strong type 1 interferon “signature” in lupus recognized the pivotal role of the innate immune system [29–31]. Dendritic cells are central in the production of type 1 interferon and have a role in the clearance and sensing of nucleic acids and immune complexes, known autoantigens in lupus. In fact, endogenous and external nucleic acids are a major antigenic stimulus in lupus. Autoantibodies targeting nucleic acid-bound antigens are one of the hallmarks of the disease. The major source of such antigens come from apoptosis and neutrophils extracellular traps (NETs) [32–34]. Excess and impaired degradation of NETs are associated with lupus severity, lupus nephritis, anti-dsDNA antibodies and complement consumption [35,36].

Apoptosis is pivotal in the pathogenesis of lupus. Apoptotic cells such as UV-light exposed keratinocytes release blebs rich in autoantigens including Ro, La, and RNP [37,38]. In *in vivo* photosensitivity for example, immunocomplexes with endogenous nucleic acids can activate plasmacytoid dendritic cells via activation of TLR7 and 9 to produce conspicuous amounts of type 1 interferon [39,40]. These particles are physiologically coated by molecules such as C1q and IgM to facilitate phagocytosis and clearance in an “immunologically silent” and anti-inflammatory environment as mediated by dendritic cells [41,42]. Excessive non-cleared apoptotic waste is associated with inflammation and autoantibody production. For example, deficiency of C1q leads to early onset SLE in children [43].

The importance of this process is further substantiated by the role of DNase1. DNase1 is a nuclease involved in the processing of the nucleic acids exposed on apoptotic blebs. In the presence of DNase1, apoptotic blebs tend to induce tolerance to self-DNA. When mutated or inhibited by anti-nucleic acids antibodies, the unprocessed nucleic acids trigger autoantibody production, type I interferon secretion, and provide a substrate for anti-dsDNA mediated immune complexes [35,44]. In fact, rare mutations in single genes involved in DNA damage repair, apoptosis, clearance of self-antigens, nucleic acid sensing, type 1 interferon production, and early complement components can lead to “monogenic lupus” and “interferonopathies” [45]. These observations highlighted the crucial role of the hypersensitivity to and inability to manage nucleic acids from dying cells as well as immunocomplexes, leading to the development of a “waste disposal” theory.

4. Diagnosis

The diagnosis of systemic lupus erythematosus is made based on a combination of typical clinical manifestations and positive serologies. Given the wide heterogeneity of clinical manifestations, several sets of

classification criteria have been developed over time for epidemiological and research purposes. However, some, such as the SLICC classification criteria, which are more sensitive, and therefore particularly useful in early diagnosis, can be useful as a diagnostic framework to confirm clinical judgment.

4.1. Classification criteria

The 1982 ACR criteria, revised in 1997, have been widely used for more than 3 decades [46,47]. The 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria [48], were evidence-based, included a “stand alone” criterion of lupus nephritis, and required at least 1 clinical (acute cutaneous lupus, chronic cutaneous lupus, oral or nasal ulcers, synovitis, serositis, proteinuria or red blood cell casts, neurologic manifestations, hemolytic anemia, leukopenia or lymphopenia, and thrombocytopenia) and at least 1 immunologic criterion (ANA, anti-dsDNA, anti-Smith, anti-phospholipid antibodies, hypocomplementemia, and direct Coombs test) for a total of 4. The SLICC classification criteria are not limited to research and are widely used for diagnosis, as they are more sensitive and more comprehensive. The 2018 EULAR criteria, developed for research only, require an ANA of 1:80 or higher, and then weight lupus manifestations (for a score of 10) [49]. Direct comparison of the 3 sets of criteria using the SLICC validation cohort showed that they perform similarly with sensitivity and specificity of 89% and 90% for the EULAR, 83% and 96% for the ACR, and 97% and 84% for the SLICC criteria, respectively [50]. A systematic review and meta-analysis including 5236 patients and 1313 controls showed that the SLICC criteria have better sensitivity (94.6% vs 89.6%) and similar specificity (95.5% vs 98.1%) for adult SLE as compared to the 1997 ACR criteria [51].

4.2. Clinical diagnosis

This section describes key organ manifestations, including some recent developments, that are important in diagnosing lupus. Additional information and reviews of each clinical manifestation of lupus can be found elsewhere [52,53].

4.2.1. Cutaneous lupus

Skin involvement in SLE occurs in almost 90% of patients and includes lupus-specific manifestations such as acute cutaneous lupus, subacute cutaneous lupus, and chronic cutaneous lupus (discoid lupus, lupus profundus, chilblain lupus, and lupus tumidus). Non-lupus-specific manifestations include alopecia, vasculitis, livedo reticularis, periungual telangiectasias, and Raynaud's phenomenon [54,55]. Most forms of cutaneous lupus share similar histological findings such as interface dermatitis with perivascular and periadnexial inflammation and may have immunoglobulin and complement deposition at the dermo-epidermal junction [55]. A biopsy is often key in the diagnosis of cutaneous lupus.

A key characteristic of cutaneous lupus erythematosus is the photosensitive distribution. Cutaneous lupus erythematosus must be differentiated from other more common photosensitive rashes such as polymorphous light eruption or rosacea. More than 50% of “photosensitive” biopsied rashes in SLE patients end up showing a non-lupus causation such as non-specific inflammatory reactions or polymorphous light eruption [56]. A true photosensitive rash in lupus is raised, delayed and long lasting. It typically occurs days after ultraviolet light exposure [57,58], tends to last for more than 3 weeks [56], and may be associated with systemic symptoms such as arthralgia or fatigue [59].

Alopecia is common in SLE, but can have multiple causes. True lupus alopecia or “lupus hair” is reversible and characterized by shortening of the frontal hair which is irregular and with broken hairs at 5–25 mm of length [60]. Discoid lupus can lead to permanent scarring lupus.

Smoking is a risk factor for SLE [17], increases the risk of discoid

lupus [61,62], increases ongoing cutaneous activity [63] and impairs the benefit of hydroxychloroquine [64].

4.2.2. Musculoskeletal involvement

Arthralgia and true synovitis are very common in SLE occurring in almost 90% [65]. It most typically presents as a symmetric polyarthritis involving the metacarpophalangeal, proximal interphalangeal, and knee joints [66]. Monoarthritis should prompt evaluation for alternative causes. Erosions are rare (unless sensitive imaging is used) and are associated with anti-cyclic citrullinated peptides antibodies [67]. Periarticular involvement including tendons and joint capsule is more common than previously understood (discovered by ultrasound and MRI) and can lead to reducible deformities known as Jaccoud's arthropathy [68–70]. Articular ultrasound and magnetic resonance may help to differentiate active inflammatory disease from tenderness due to fibromyalgia and quantify the burden of disease [68–70].

Importantly, fibromyalgia, fibromyalgias (the tendency to respond to illness and psychosocial stress with fatigue and widespread pain), and depression are common in lupus patients and associate with musculoskeletal pain; these do not track with disease activity and should not be misinterpreted as such [71,72].

4.2.3. Renal disease

Renal involvement is present in about 50% of patients with lupus with a predilection for certain ethnic groups such as African-Americans (70%) [73]. Early detection and treatment are paramount since lupus nephritis is a major cause of morbidity and mortality in SLE and delayed diagnosis is a risk factor for end-stage renal disease [74,75]. Renal disease is suspected when there is proteinuria [52,75]. However, lupus nephritis (class III, IV, and V) can be present in 25% of SLE patients without clinical signs of renal disease [76]. Urine protein levels above 500 mg/24 h are associated with histopathological lupus nephritis and should prompt a renal biopsy [77]. Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis, it is easier to routinely measure, and it is highly correlated with the 24 h proteinuria [78]. In addition, clinical and serological (hypocomplementemia and elevation of anti-dsDNA antibodies) activity may further suggest lupus nephritis and is associated with higher risk histological features [77,79]. Anti-C1q antibodies are strongly associated with renal involvement in SLE, may predict flares, and their absence has a negative predictive value of nearly 100% [80–82].

Renal biopsy is essential to confirm the diagnosis, exclude alternative causes, evaluate for active inflammation versus irreversible damage, inform prognosis, and guide treatment. Lupus nephritis is classified based on clinicopathological correlations [83]. The Renal Pathology Society/International Society of Nephrology (or RPS/ISN) classification include 6 classes: minimal mesangial lupus nephritis, mesangial proliferative lupus nephritis, focal lupus nephritis, diffuse lupus nephritis, membranous nephropathy, and advanced sclerosing lupus nephritis [83]. Additional renal diseases associated with lupus include lupus podocytopathy [84], tubulointerstitial nephritis, vascular disease (such as thrombotic microangiopathy, vasculitis, or atherosclerosis) [85], and collapsing glomerular sclerosis [86].

4.2.4. Central nervous system disease

A wide array of neuropsychiatric manifestations has been associated with SLE. However, only a few of them are more specific for SLE and are helpful for diagnosis [87,88]. These include seizures, psychosis, mononeuritis multiplex, myelitis, peripheral or cranial neuropathy, and acute confusional state [87,88]. Importantly, these require exclusion of other known causes.

In addition to clinical evaluation, magnetic resonance imaging (MRI) and cerebral spinal fluid analysis are important diagnostic tools. Central nervous system MRI is helpful to detect chronic microvascular changes, infarcts, hemorrhages, cortical atrophy, edema, abscesses, transverse and longitudinal myelitis [89,90]. Detection of long T2 of

the gray matter (suggesting edema) or gadolinium enhancement in patients with active manifestations (seizures, psychosis, coma) may suggest activity, but generally, MRI cannot distinguish active from previous disease [89,91,92].

Identification of abnormal cerebrospinal fluid IgG and oligoclonal bands may help to identify active neuropsychiatric lupus [93]. Infection, metabolic-toxic and malignancy conditions always need to be considered in the differential diagnosis.

Up to 80% of SLE patients have cognitive impairment [94]. Formal psychometric testing and a psychiatric evaluation may be helpful to detect cognitive impairment and/or functional disorders [94,95]. Surprisingly, cognitive impairment (mild to moderate) is present in the majority of patient at the time of diagnosis, and does not worsen during follow up [96]. The most important correlate of cognitive impairment is depression [97].

5. Management

5.1. Principles

The goals of treatment in lupus are 1) maintain lowest degree of activity using immunomodulators, immunosuppression as appropriate and avoiding known triggers, 2) prevent organ damage from active lupus, 3) reduce comorbidities secondary to lupus and its treatment, especially accelerated atherosclerosis, the major cause of death, and 4) address fatigue and pain, which often are not associated with active lupus. Early initiation of treatment as well as partnership with the patient towards these shared goals is essential. This translates into avoidance of known triggers of flares, the need for sun protection, maximization of immunomodulators (hydroxychloroquine and vitamin D, including monitoring for adherence), avoidance of maintenance prednisone > 6 mg daily, and control of active disease with immunosuppression or biologics when required. Here, we review the rationale for current and future treatments.

5.2. Immunomodulators

Immunomodulators can favorably regulate the immune system in SLE without increasing the risk of infection or malignancy.

5.2.1. Hydroxychloroquine

Hydroxychloroquine pleiotropically modulates the immune response by inhibition of B cell receptor and TLR signaling as well as intracellular TLR-3 and-7 activation, fundamental in nucleic acid sensing [98–101]. It increases the lysosomal pH interfering with MHC-antigen binding, thus processing of autoantigens, as well as secretions of cytokines [102–104]. Hydroxychloroquine exerts an anti-type 1 interferon effect by interfering with the STING pathway [105].

Hydroxychloroquine is the cornerstone of medical therapy in lupus. It should be used in every patient unless there is a clear contraindication. It is the only medication shown to increase survival in lupus patients [106–109]. It has been shown to reduce lupus flares [110], prevent organ damage [111] including cardiovascular events [112], triple mycophenolate response in lupus nephritis [113], prevent seizures [114,115] and reduces the risk of developing neuropsychiatric lupus [116]. Hydroxychloroquine improves skin manifestations [117,118] and arthritis [119]. Hydroxychloroquine has a favorable effect on lipids [102,120–122], reduces insulin resistance [123] and the risk of thrombosis [124,125], and has a favorable effect on bone density [108,126].

Hydroxychloroquine is non immunosuppressive and does not increase the risk of infection or malignancy [127,128]. Retinal toxicity is a rare complication increasing after 20 years duration of treatment [129]. Retinal screening occurs at baseline, at 5 years, and then yearly [130]. Optical coherence tomography is the preferred screening test [36]. Hyperpigmentation can occur. Very rare complications include

cardiomegaly and myopathy.

5.2.2. Vitamin D

Vitamin D should be supplemented in all SLE patients with insufficiency or deficiency, for its immunomodulatory and anti-fibrotic effects. Vitamin D immunomodulatory properties are mediated by the vitamin D3 receptor (VDR) in multiple immune cells lineages including monocytes, dendritic cells, and activated T cells as well as in the skin, vasculature and other tissues [131]. *In vitro*, vitamin D exerts an anti-inflammatory and anti-proliferative effect by promoting a Th1 (TNF- α , IL-2, IFN- γ) to Th2 (IL-4, IL-5, IL-10, GATA3) polarization as well as Th17 (IL12, IL23, IL-6, 17) to Treg (IL-10, TGF- β , FoxP3, CTLA4) state [132]. It affects the development and function of NKT cells [133].

In addition, vitamin D may act as an anti-fibrotic agent. Vitamin D deficiency is associated with increased risk of multiorgan fibrosis including, among others, the kidneys and the lungs [134]. Importantly, patients with lupus nephritis refractory to mycophenolate have increased expression of profibrotic pathways in the affected kidneys [135] suggesting that renal tissue could be rescued by targeting such pathways. Vitamin D supplementation prevented fibrosis in animal models and inhibits pro-fibrotic pathways mediated by TGF- β and Ras [134,136].

Vitamin D deficiency is common in patients with SLE [137]. Some VDR polymorphisms are associated with lower serum vitamin D levels and have been associated with SLE [138]. In patients with lupus, vitamin D deficiency correlates with increased disease activity and fatigue [139,140] as well as an increased risk for thrombosis, including from antiphospholipid antibodies [141,142]. Importantly, supplementation of vitamin D is associated with reduction of proteinuria, higher complement levels, and improvement in global disease activity in SLE as demonstrated in an observational cohort and in a randomized controlled study [143,144]. Supplementation should be aimed to a 25(OH) vitamin D level of 40 ng/ml [143,144]. Vitamin D supplementation is safe [143] and should be continued indefinitely. Vitamin D levels should be monitored periodically to assess adequate absorption and dosing and adherence.

5.2.3. Dehydroepiandrosterone (DHEA)

DHEA is an adrenal hormone regulated by ACTH [145]. It is an important precursor of both estrogens and androgens via peripheral conversion [146]. Women with lupus tend to have lower levels of androgens, higher estradiol, lower DHEA and DHEA-S (its metabolite), independently of corticosteroid use [147,148]. In addition, DHEA supplementation has been associated with regulation of proinflammatory cytokines (IL-2, IL-1, IL-6, TNF- α) and may reduce antibody production in mice [149–152].

Many of the several randomized clinical trials in women with SLE showed a modest improvement in disease activity along with improvement in cytokine profile and bone density [153,154]. DHEA should not be used in postmenopausal women since it may increase the risk of hormone sensitive malignancies. There is no evidence to support DHEA use in men.

5.3. Corticosteroids

Corticosteroids affect all components of the immune system [155]. High dose or “pulsed” corticosteroids are important to rapidly ablate the autoimmune response in life or organ threatening manifestations such as some cases of nephritis, vasculitis, central nervous system lupus, myocarditis, or alveolitis, among others. In lupus nephritis for example, pulsed therapy (250–1000 mg IV daily for 3 days) was previously recommended along with cyclophosphamide or mycophenolate for induction, but there is no consensus on an oral maintenance regimen [156,157]. The “rituxilup” protocol showed that lupus nephritis remission can be induced without any oral corticosteroids using rituximab and mycophenolate suggesting that corticosteroids might not be

necessary to control even severe lupus manifestations [158]. In the recent voclosporin phase 2 clinical trial, only 25 mg of prednisone was used [159]. Importantly, any of the studied immunosuppressants agents (cyclophosphamide, azathioprine, mycophenolate, tacrolimus) is better than corticosteroids alone to prevent end stage renal disease [160].

Oral corticosteroids should be avoided as much as possible. In lupus patients, 80% of organ damage after diagnosis is directly or indirectly attributable to prednisone [161]. Doses of even 10–20 mg daily increase the risk of cardiovascular events [162] and any dose above 6 mg increases later organ damage by 50% [163]. Even low doses, over time, increase cataracts, osteoporosis, fractures and coronary artery disease [164].

Intramuscular triamcinolone, or a brief 1-week methylprednisolone dose pack, is effective for management of most mild to moderate flares. Results from the FLOAT trial showed that a single intramuscular triamcinolone 100 mg injection is a faster acting and effective alternative to oral maintenance corticosteroids [165]. As it is released slowly, its effect lasts for about 1 month and has equipotency of approximately 2 mg of prednisone daily.

5.4. Cytotoxic-immunosuppressants

5.4.1. Cyclophosphamide

Cyclophosphamide is a highly toxic alkylating agent that depletes T and B cells and suppresses antibody production [166]. It was more widely used in the past for the induction and maintenance of lupus nephritis [167,168] and other severe lupus manifestations such as central nervous system lupus [169]. However, it has now been largely replaced by less toxic immunosuppressive medications such as mycophenolate, calcineurin inhibitors, and azathioprine for nephritis and rituximab for severe central nervous system lupus [170,171]. Cyclophosphamide is associated with premature ovarian failure, hemorrhagic cystitis, increased risk of bladder and other malignancies, and leukopenia along with an increased risk of infections [172].

5.4.2. Azathioprine

Azathioprine is a purine analogue. It is converted *in vivo* to 6-mercaptopurine followed by thioinosinic acid and 6-thioguanine which are incorporated into DNA and RNA, inhibiting their synthesis. Besides its antimetabolite role, azathioprine may have a tolerogenic effect by inhibiting CD28-mediated signal 2 in T cells [173].

Azathioprine has been commonly used in renal and extrarenal lupus since the late 1960s. In two small randomized studies, azathioprine compared to corticosteroids alone was shown to reduce mortality, rate of flares and corticosteroid use, including patients with severe renal or central nervous system disease [174,175]. In the following decades, its use in induction in lupus nephritis waned given its inferiority to cyclophosphamide [176,177]. Azathioprine was inferior to mycophenolate in the ALMS trials and equal in the MAINTAIN trial [178,179].

In extrarenal lupus, azathioprine is widely used as a corticosteroid sparing agent [180]. However, a recent non-blinded randomized controlled study showed that mycophenolate was superior to azathioprine to control disease activity and prevent flares (renal and extrarenal) while maintaining a similar side effect profile [181].

Azathioprine remains an excellent choice to control renal and extrarenal disease during pregnancy as the metabolite 6-MMP is not generated in the fetus [182,183].

5.4.3. Methotrexate

Methotrexate is an antimetabolite that interferes with DNA synthesis, repair, and replication by irreversibly binding to dihydrofolate reductase, thus reducing purine synthesis. However, the mechanism of its anti-inflammatory effects goes beyond arresting the cell cycle by folate depletion and is not completely understood [184]. For instance, co-administration of folate does not impair its efficacy, while mitigating side effects. Low-dose methotrexate has pleiotropic effects involving

increased anti-inflammatory adenosine signaling, apoptosis of activated lymphocytes, reduction of circulating pro-inflammatory T-cells, reduction of adhesion molecules on endothelial and synovial cells, reactive oxygen species, and others [184].

In lupus, methotrexate has been used since the 1960s [185]. Combined evidence from 3 small randomized trials and several observational studies showed that methotrexate reduced disease activity, was corticosteroid sparing, had efficacy for joint and skin disease, and ameliorated anti-dsDNA and complement levels [186]. Methotrexate showed a modest steroid sparing activity in a randomized controlled trial [187].

5.4.4. Mycophenolate

Mycophenolate preferentially depletes guanoside nucleotides in T and B cells inhibiting proliferation. It suppresses lymphocyte and monocyte recruitment to inflamed tissue. It inhibits inducible nitric oxide synthase which may curtail nitric oxide oxidative tissue damage mediated by macrophages [188].

Mycophenolate is effective for induction and maintenance of lupus nephritis [178,179,189–191]. The ALMS trial (n = 140) showed that 22.5% of patients treated with mycophenolate achieved complete renal remission at 24 weeks compared to 5.8% in the cyclophosphamide group [190]. The larger ALMS lupus nephritis induction trial showed similar efficacy of mycophenolate compared to cyclophosphamide [191]. Mycophenolate had a better safety profile. This was confirmed by a recent Cochrane systematic review, although with low certainty evidence [192]. This review also confirmed that mycophenolate is superior to azathioprine in preventing nephritis relapses. Mycophenolate is also effective in extrarenal lupus in all the analyzed domains in multiple case series and in a post-hoc analysis of the ALMS trial [193,194].

5.4.5. Calcineurin inhibitors

Calcineurin inhibitors target T cells by blocking the inhibition of calcineurin [195]. This prevents translocation of transcription factors such as nuclear factor of activated T-cells (NFAT) resulting in T cells inhibition with reduction of IL-1b, IFN- γ , IL-6 and IL-10. B cell activation is also impaired along with class switching and immunoglobulin production. Furthermore, calcineurin inhibitors affect the kidneys directly by stabilizing podocytes, reducing mesangial proliferation, and improving proteinuria [196–198].

Calcineurin inhibitors are commonly used to prevent transplant rejection. In lupus, tacrolimus has been used, alone or in combination with mycophenolate, more extensively than cyclosporine given its better side effects profile [199]. However, both have significant variability in plasma concentration and require monitoring.

Multiple small RCTs showed that lupus nephritis induction with calcineurin inhibitors (cyclosporine or tacrolimus) is as effective as cyclophosphamide or mycophenolate [200–203]. A recent meta-analysis suggested a possible superiority of tacrolimus over cyclophosphamide [204]. A larger trial comparing mycophenolate vs tacrolimus in 150 Chinese patients with active class III/IV showed similar complete response rates at 6 months (59% vs 62%, respectively) and side effects [205].

Combination of calcineurin inhibitors and mycophenolate is used to prevent graft rejection and is also effective in refractory lupus nephritis in Caucasian and African American patients [206–208]. In a large RCT, 368 Chinese patients with class III/IV/V lupus nephritis were randomized to receive a combination of tacrolimus (4 mg/day) and low dose mycophenolate (1 g/day) (“multitarget”) or monthly IV cyclophosphamide (0.5–1 g/m²) [209]. After 6 months, complete remission was achieved in 45.9% vs 25.6%, and overall response in 83.5% vs 63% in the multitarget and cyclophosphamide, respectively. More patients withdrew from the multitarget arm, mostly due to pneumonias and zoster reactivation [209].

Calcineurin inhibitors have also been proven effective for

maintenance therapy of lupus nephritis [210,211], as well as for pure membranous lupus nephritis with a significant antiproteinuric effect [205,212–215]. They are recommended by EULAR [157].

Voclosporin is a new calcineurin inhibitor. It has greater pharmacological potency, faster elimination and less variability in blood concentration. It is non-inferior to tacrolimus in preventing kidney transplant rejection [216]. The AURA phase IIb study randomized 265 patients with active lupus nephritis to receive voclosporin or placebo in addition to mycophenolate and corticosteroids [159,217]. Both voclosporin doses showed higher complete remission rate than mycophenolate alone at 24 and 48 weeks (48 weeks complete remission 40%, 49%, and 24% in the high dose, low dose, and mycophenolate alone arm, respectively). Glomerular filtration rate decreased with voclosporin. There was an imbalance of death in the low dose voclosporin arm. A phase III trial (AURORA) is ongoing.

5.5. Biologics and small molecules

5.5.1. Available

5.5.1.1. Rituximab. Autoantibodies and immune complex formation are an immunological hallmark of lupus. B cells have been targeted in SLE for years with immunosuppressants such as cyclophosphamide and mycophenolate. Targeted therapies toward B cells that avoid broad immunosuppression are the goal.

Rituximab is an anti-CD20 monoclonal antibody that leads to peripheral B cell depletion. Several observational studies showed benefit in renal and non-renal lupus [218,219]. Two large randomized placebo-controlled trials in renal and non-renal lupus failed to meet their primary outcomes. In the EXPLORER non-renal trial [220], the primary (proportion of patients achieving complete or partial remission based on BILAG score) and secondary endpoints were not met. B-cell depletion was obtained in about 90% of treated patients. Rituximab did reduce anti-dsDNA titers RCT improved C3 and C4 levels.

In the LUNAR renal trial [221], 144 patients with class III or IV lupus nephritis were randomized to receive rituximab (1000 mg on day 1, 15, 168, and 182) or placebo in addition to mycophenolate and corticosteroids. The rituximab group failed to achieve the primary outcome defined as better overall (complete and partial) renal response compared to mycophenolate alone at 52 weeks (57% vs 46%, p = 0.18). Further analysis showed that rituximab did reduce proteinuria better than mycophenolate alone at 18 months and reduced the need for rescue cyclophosphamide (8/72 in the placebo group vs 0/72 for rituximab).

The disappointing results led to the consideration of the issue of reconstitution of B cells after rituximab [222]. The surge of BAFF upon depletion of B cells with rituximab may contribute to the lack of sustained response to rituximab [223–225]. This provided the rationale for SynBioSe, a proof of concept phase 2A trial of rituximab followed by belimumab in patients with refractory severe lupus nephritis [226]. Eleven out of 16 patients showed a renal response, 5 with complete response. The renal response was paralleled by amelioration of immune-complex mediated NETs formation. In the CALIBRATE trial, patients with refractory lupus nephritis were treated with rituximab, cyclophosphamide and corticosteroids followed by either belimumab or placebo. This did not show a benefit of belimumab, with 24 week renal responses of 24% vs 23% [227].

Evidence for the efficacy of rituximab comes from “rituxilup”, an oral corticosteroid-avoidance protocol to treat lupus nephritis with mycophenolate and rituximab. In this prospective observational single-center cohort study, partial or complete remission was achieved in 45 of 50 patients by a median time of 37 weeks [158].

5.5.1.2. Belimumab. B cells maturation, Ig-class switching, and antibody production are most potently driven by antigen specific T cells. Since T cells tolerance is much more strictly regulated, such T cell dependence should ensure that autoreactive naïve B cells that escaped

central tolerance will be eliminated by lack of stimulation. However, T cell-independent pathways such as B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) may bypass T cells in the selection of autoreactive B cells. BAFF exists in a soluble and membrane bound form and is produced by antigen presenting cells (dendritic cells, B-cells, monocyte/macrophages, plasmacytoid dendritic cells), neutrophils, activated T cells and endothelial cells [228]. BAFF provides essential activation and survival signals via NF κ B and MAP-K pathways to B cells as mediated by 3 receptors: BAFFR, TACI and BCMA. BAFFR ligation provides the strongest signal while TACI and BCMA also bind to APRIL [229]. Importantly, patients with lupus have higher circulating BAFF and APRIL levels and the BAFF level is predictive of flares [230]. BAFF-transgenic mice have a lupus-like phenotype independent of T cells [231].

Two large phase 3 RCT, BLISS-52 and BLISS-76, assessed the SLE responder index at 52 weeks in patients with non-renal lupus [232,233]. In both trials, there was a higher response rate with the higher dose of belimumab (10 mg/kg) compared to standard of care (BLISS-52: n = 867, 58% vs 44%, p = 0.006; BLISS-76: n = 819, 43.2% vs 33.5%, p = 0.017). Belimumab also significantly reduced the number of flares. In addition, belimumab normalized anti-dsDNA in up to 17–25% (placebo 6–8%) and normalized C3 in 34–44% (vs 14–21%) and C4 in 43–46% (vs 17–19%). Belimumab decreased circulating B cells and CD20+ /CD27^{bright} short lived plasma cells were decreased by > 50% and up to 43%, respectively. Pooled data analysis of both trials showed that combined hypocomplementemia and anti-dsDNA positivity was the best predictor of response to belimumab [234]. Based on these results, belimumab became the first new drug in the last five decades to be approved by the EMA and FDA (and later by NICE) for the treatment of active non-renal lupus despite standard therapy.

5.5.2. Currently studied

5.5.2.1. Anifrolumab. Type 1 interferon signaling is mediated by the type I IFN- $\alpha/\beta/\omega$ receptor (IFNAR). Anifrolumab is a monoclonal antibody blocking IFNAR. In a phase 2b trial, 305 lupus patients were randomized to receive placebo or one of two dosages of anifrolumab [235]. At 24 weeks, 34% and 29% of patients receiving anifrolumab (300 mg and 1000 mg every 4 weeks, respectively), while only 17.6% in the placebo group, achieved the primary outcome of SRI-4 response with sustained reduction of oral corticosteroids. The effect was greater in patients with the interferon signature at baseline. Both skin and joint disease showed a favorable response. In addition, anifrolumab was associated with decreased anti-dsDNA titers and higher C3 levels. There was a mild increased risk of viral infections, including influenza and herpes zoster. However, the first phase III trial (TULIP 1) did not reach its primary end point of decreasing the SRI-4 [236]. TULIP 2 is currently under way.

5.5.2.2. Ustekinumab. There is increased Th17 activity in lupus. Serum IL-17 and IL-23 levels are higher in SLE and correlate with disease activity [28]. IL-17-producing cells are present in biopsies from lupus nephritis [28]. Double negative T cells are also a source of IL-17. STAT3, which is downstream to IL-23 stimulation, is upregulated in lupus [237], and promotes IL-17 production as well as differentiation toward Th17 and Tfh [238]. Tfh are expanded in SLE and have been implicated in the overstimulation of B cells [239]. IL-23 promotes the development of double negative T cells [240] and impairs the production of IL-2 suggesting a possible indirect effect on the production of Tregs [241].

The IL-23/Th17 axis can be disrupted by ustekinumab, a monoclonal antibody blocking IL-12 and IL-23 currently approved to treat psoriasis, psoriatic arthritis and inflammatory bowel disease. In a phase 2 trial, 102 patients with SLE were randomized (3:2) to ustekinumab vs placebo. At 24 weeks, 60% of ustekinumab-treated patients achieved the primary endpoint, SLE responder index-4 (SRI-4) compared to 31% in the standard of care group (p = 0.0046). Subgroup analysis showed

significant improvement in skin and joint scores. Ustekinumab improved C3 and reduced anti-dsDNA levels [242].

5.5.2.3. Baricitinib. The Janus kinases (JAKs) are a family of tyrosine kinases mediating intracellular signaling of several cytokines via the JAK-STAT pathway. Inhibition of a single JAK may lead to blocking the downstream effect of several cytokines at the time. However, this is a redundant system in which a group of cytokines may signal through different JAKs and different JAKs mediate signaling from different groups. At present, baricitinib and tofacitinib are FDA approved for the treatment of rheumatoid arthritis. Baricitinib is a reversible inhibitor of JAK1 and JAK 2. These mediate signaling for type 1 interferons, IFN- γ , IL-6, IL-12, and IL-23 among others [243]. An international, multicenter, double-blind, placebo-controlled phase 2 trial assessed the efficacy of baricitinib in patients with SLE. The primary outcome was the proportion of patients achieving resolution of rash or arthritis at 24 weeks, defined by SLEDAI-2K [244]. Three-hundred and fourteen patients with inadequate control despite standard of care were included. The primary outcome was achieved in a statistically significant higher proportion of patients treated with baricitinib 4 mg daily, but not 2 mg daily, as compared to placebo (67% vs 58% vs 53%, respectively). Most of the results were driven by the baricitinib effect on arthritis as no significant difference was noted on skin scores. The frequency of flares was also lower in the 4 mg group compared to placebo (33% vs 51%). There were more serious infections in the 4 mg arm (6%) compared to the 2 mg (2%) and placebo (1%). There was 1 deep venous thrombosis (1%) detected in the 4 mg arm.

5.5.2.4. Atacicept. Atacicept is a TACI-Ig fusion protein that inhibits B cells by dual inhibition of APRIL and BLyS. In a phase 1b trial, atacicept showed a dose dependent reduction in circulating B cells and immunoglobulins [245]. In the ADDRESS II, a phase 2b trial, 306 patients were randomized to receive weekly subcutaneous atacicept (75 mg or 150 mg) or placebo [246]. Atacicept was associated with a trend toward better SRI-4 response at 4 weeks compared to placebo, especially in individuals with high disease activity, serologically active disease, or both. For example, in the serologically active group, 62% of patients treated with atacicept achieved SRI-4 at 24 weeks compared to 24% in the placebo arm [246].

5.6. Lifestyle

Some of lupus management is non-pharmacological [247]. Patients should avoid sun exposure using protective garments and sunscreen of at least SPF 50 (as demonstrated in a randomized clinical trial [248]).

Fibromyalgia and “fibromyalgia-ness” (tendency to respond to illness and psychosocial stress with fatigue, general increase in symptoms, and widespread pain) is increased in SLE [249,250]. Regular exercise, stretching and can help to improve fatigue, cognitive dysfunction, and pain from fibromyalgia [251–253].

5.7. Prevention of comorbidities

Lupus confers a 2.4-fold increase in all-cause mortality. The number one cause of death in lupus is cardiovascular events, followed by infections, and finally by renal and respiratory complications of lupus [74].

The risk of cardiovascular events is increased 2.66 fold [162]. Therefore, aggressive management of traditional (smoking, obesity, diabetes mellitus, hypertension, dyslipidemia) and lupus (lupus activity, antiphospholipid antibodies, homocysteinemia, excessive corticosteroid use) modifiable cardiovascular risk factors is paramount to prevent early death [254].

Homocysteinemia is present in 15% of patients [255] and has an independent association with cardiovascular risk [256–258], renal injury and fibrosis [259,260], and is associated with higher prevalence of

myocardial infarction and thrombosis in patients with antiphospholipid antibodies [261]. Hyperhomocysteinemia is an independent risk factor for cardiovascular disease in patients with lupus [255].

Infections are common in lupus, particularly from encapsulated bacteria [262]. Typical organisms are the most common causal agents but opportunistic bacterial, mycobacterial, protozoal, fungal and viral infection are also increased [263]. Pneumonia, especially from *Streptococcus pneumoniae*, is common in lupus and is associated with excess mortality [74,263]. In addition to the local immunization schedule, pneumococcal and influenza vaccination should be followed.

Osteoporosis and fragility fractures are higher in lupus [264–266]. Notably, fracture risk calculators may underestimate in lupus [267]. Optimal bone health should be pursued recommending smoking cessation, optimal vitamin D levels, adequate dietary calcium intake (rather than supplementation [268]), weight bearing exercise, avoidance of corticosteroids, bone density screening according to risk and treatment with DHEA (never in men) and bisphosphonate as appropriate [154,267].

6. Future perspectives and personalized medicine

The more granular understanding of the molecular basis of lupus pathogenesis has led to several new promising treatments that are undergoing late phase clinical testing. These recent phase 2 trials underlined how targeting a specific pathway may elicit dramatically different responses in patient subgroups. Precise characterization of disease phenotypes based on molecular and clinical features is crucial to design personalized treatment. The Accelerated Medicine Partnership (AMP), for example, is an ongoing effort to identify the molecular pathways, at the single cell level, involved in lupus nephritis [269]. This may help to redefine the way we classify SLE and lupus nephritis and identify precise predictors of treatment response. We expect that the understanding of the heterogeneity of autoimmunity in lupus will lead to more effective and less toxic regimens in the future.

Funding

The Hopkins Lupus Cohort is funded by NIH AR 69572.

Disclosures

None.

References

- [1] M. Petri, Epidemiology of systemic lupus erythematosus, *Best Pract. Res. Clin. Rheumatol.* 16 (2002) 847–858, <https://doi.org/10.1053/berh.2002.0259>.
- [2] A.E. Johnson, C. Gordon, R.G. Palmer, P.A. Bacon, The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth, *Arthritis Rheum.* 38 (1995) 551–558, <https://doi.org/10.1002/art.1780380415>.
- [3] N. Danchenko, J. Satia, M. Anthony, Epidemiology of systematic lupus erythematosus: a comparison of worldwide disease burden, *Lupus* 12 (2006) 308–318 <http://lup.sagepub.com.proxygw.wrlc.org/content/15/5/308.full.pdf+html>.
- [4] D.P.M. Symmons, Occasional series: lupus around the World frequency of lupus in people of African origin, *Lupus* 4 (1995) 176–178, <https://doi.org/10.1177/096120339500400303>.
- [5] G.J. Pons-Estel, G.S. Alarcón, L. Scofield, L. Reinlib, G.S. Cooper, Understanding the epidemiology and progression of systemic lupus erythematosus, *Semin. Arthritis Rheum.* 39 (2010) 257–268, <https://doi.org/10.1016/j.semarthrit.2008.10.007>.
- [6] E. Krishnan, H.B. Hubert, Ethnicity and mortality from systemic lupus erythematosus in the US, *Ann. Rheum. Dis.* 65 (2006) 1500–1505, <https://doi.org/10.1136/ard.2005.040907>.
- [7] E.D. Ferucci, J.M. Johnston, J.R. Gaddy, L. Sumner, J.O. Poverer, T.L. Choromanski, C. Gordon, S.S. Lim, C.G. Helmick, Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007–2009, *Arthr. Rheumatol.* 66 (2014) 2494–2502, <https://doi.org/10.1002/art.38720>.
- [8] S.S. Lim, A.R. Bayakly, C.G. Helmick, C. Gordon, K.A. Easley, C. Drenkard, The incidence and prevalence of systemic lupus erythematosus, 2002–2004: the Georgia lupus registry, *Arthr. Rheumatol.* 66 (2014) 357–368, <https://doi.org/10.1002/art.38239>.
- [9] E.C. Somers, W. Marder, P. Cagnoli, E.E. Lewis, P. DeGuire, C. Gordon, C.G. Helmick, L. Wang, J.J. Wing, J.P. Dhar, J. Leisen, D. Shaltis, W.J. McCune, Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program, *Arthr. Rheumatol.* 66 (2014) 369–378, <https://doi.org/10.1002/art.38238>.
- [10] C.G. Helmick, D.T. Felson, R.C. Lawrence, S. Gabriel, R. Hirsch, C.K. Kwoh, M.H. Liang, H.M. Kremers, M.D. Mayes, P.A. Merkel, S.R. Pillemer, J.D. Reveille, J.H. Stone, Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I, *Arthritis Rheum.* 58 (2008) 15–25, <https://doi.org/10.1002/art.23177>.
- [11] G.C. Tsokos, M.S. Lo, P.C. Reis, K.E. Sullivan, New insights into the immunopathogenesis of systemic lupus erythematosus, *Nat. Rev. Rheumatol.* 12 (2016) 716–730, <https://doi.org/10.1038/nrrheum.2016.186>.
- [12] E. Generali, A. Ceribelli, M.A. Stazi, C. Selmi, Lessons learned from twins in autoimmune and chronic inflammatory diseases, *J. Autoimmun.* 83 (2017) 51–61, <https://doi.org/10.1016/j.jaut.2017.04.005>.
- [13] Y. Ghodke-Puranik, T.B. Niewold, Immunogenetics of systemic lupus erythematosus: a comprehensive review, *J. Autoimmun.* 64 (2015) 125–136, <https://doi.org/10.1016/j.jaut.2015.08.004>.
- [14] R.A. Burger, A.R. Torres, R.P. Warren, V.D. Caldwell, B.G. Hughes, Echinacea-induced cytokine production by human macrophages, *Int. J. Immunopharmacol.* 19 (1997) 371–379, [https://doi.org/10.1016/S0192-0561\(97\)00061-1](https://doi.org/10.1016/S0192-0561(97)00061-1).
- [15] K. Spelman, J.J. Burns, D. Nichols, N. Winters, S. Ottersberg, M. Tenborg, Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators, *Altern. Med. Rev.* 11 (2006) 128–150, <https://doi.org/10.1016/j.cyto.2017.10.019>.
- [16] M. Petri, J. Allbritton, Antibiotic allergy in systemic lupus erythematosus: a case-control study, *J. Rheumatol.* 19 (1992) 265–269 <http://www.ncbi.nlm.nih.gov/pubmed/1629825>.
- [17] K.H. Costenbader, D.J. Kim, J. Peerzada, S. Lockman, D. Nobles-Knight, M. Petri, E.W. Karlson, Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis, *Arthritis Rheum.* 50 (2004) 849–857, <https://doi.org/10.1002/art.20049>.
- [18] J. Blomberg, O. Nived, R. Pipkorn, A. Bengtsson, D. Erlinge, G. Sturfelt, Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus: correlation with autoantibodies and clinical manifestations, *Arthritis Rheum.* 37 (1994) 57–66 <http://www.ncbi.nlm.nih.gov/pubmed/7510483>.
- [19] G.S. Cooper, C.G. Parks, Occupational and environmental exposures as risk factors for systemic lupus erythematosus, *Curr. Rheumatol. Rep.* 6 (2004) 367–374 <http://www.ncbi.nlm.nih.gov/pubmed/15355749>.
- [20] J.A. James, B.R. Neas, K.L. Moser, T. Hall, G.R. Bruner, A.L. Sestak, J.B. Harley, Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure, *Arthritis Rheum.* 44 (2001) 1122–1126, [https://doi.org/10.1002/1529-0131\(200105\)44:5<1122::AID-ANR193>3.0.CO;2-D](https://doi.org/10.1002/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D).
- [21] C.G. Parks, G.S. Cooper, L.A. Nylander-French, W.T. Sanderson, J.M. Dement, P.L. Cohen, M.A. Dooley, E.L. Treadwell, E.W. St. Clair, G.S. Gilkeson, J.A. Hoppin, D.A. Savitz, Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States, *Arthritis Rheum.* 46 (2002) 1840–1850, <https://doi.org/10.1002/art.10368>.
- [22] W. Crowe, P.J. Allsopp, G.E. Watson, P.J. Magee, J.J. Strain, D.J. Armstrong, E. Ball, E.M. McSorley, Mercury as an environmental stimulus in the development of autoimmunity – a systematic review, *Autoimmun. Rev.* 16 (2017) 72–80, <https://doi.org/10.1016/j.autrev.2016.09.020>.
- [23] M.A. Zarnbinksi, R.P. Messner, J.S. Mandel, Anti-dsDNA antibodies in laboratory workers handling blood from patients with systemic lupus erythematosus, *J. Rheumatol.* 19 (1992) 1380–4 <http://www.ncbi.nlm.nih.gov/pubmed/1433005>.
- [24] S.-H. Chiou, J.-L. Lan, S.-L. Lin, D.-Y. Chen, N.-Y. Tsai, C.-Y. Kuan, T.-Y. Lin, F.-J. Lin, W.-M. Lee, T.-J. Chang, Pet dogs owned by lupus patients are at a higher risk of developing lupus, *Lupus* 13 (2004) 442–449, <https://doi.org/10.1191/0961203303lu1039oa>.
- [25] H. Song, F. Fang, G. Tomasson, F.K. Arnberg, D. Mataix-Cols, L. Fernández de la Cruz, C. Almqvist, K. Fall, U.A. Valdimarsdóttir, Association of stress-related disorders with subsequent autoimmune disease, *Jama* 319 (2018) 2388–2400, <https://doi.org/10.1001/jama.2018.7028>.
- [26] A.L. Roberts, S. Malspeis, L.D. Kubzansky, C.H. Feldman, S.-C. Chang, K.C. Koenen, K.H. Costenbader, Association of trauma and posttraumatic stress disorder with incident systemic lupus erythematosus in a longitudinal cohort of women, *Arthr. Rheumatol.* (Hoboken, N.J.). 69 (2017) 2162–2169, <https://doi.org/10.1002/art.40222>.
- [27] M.K. Crowe, Etiology and Pathogenesis of Systemic Lupus Erythematosus, tenth ed., Elsevier Inc., 2017, <https://doi.org/10.1016/B978-0-323-31696-5.00079-6>.
- [28] T. Katsuyama, G.C. Tsokos, V.R. Moulton, Aberrant T cell signaling and subsets in systemic lupus erythematosus, *Front. Immunol.* 9 (2018), <https://doi.org/10.3389/fimmu.2018.01088>.
- [29] E.C. Baechler, F.M. Batliwalla, G. Karypis, P.M. Gaffney, W. A. Ortmann, K.J. Espe, K.B. Shark, W.J. Grande, K.M. Hughes, V. Kapur, P.K. Gregersen, T.W. Behrens, Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 2610–2615, <https://doi.org/10.1073/pnas.0337679100>.
- [30] L. Bennett, A.K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, V. Pascual, Interferon and granulopoiesis signatures in systemic lupus erythematosus blood, *J. Exp. Med.* 197 (2003) 711–723, <https://doi.org/10.1084/jem.20021553>.

- [31] K.A. Kirou, C. Lee, S. George, K. Louca, I.G. Papagiannis, M.G.E. Peterson, N. Ly, R.N. Woodward, K.E. Fry, A.Y.-H. Lau, J.G. Prentice, J.G. Wohlgenuth, M.K. Crow, Coordinate overexpression of interferon- γ -induced genes in systemic lupus erythematosus, *Arthritis Rheum.* 50 (2004) 3958–3967 <http://doi.wiley.com/10.1002/art.20798>.
- [32] M.J. Kaplan, M. Radic, Neutrophil extracellular traps: double-edged swords of innate immunity, *J. Immunol.* 189 (2012) 2689–2695, <https://doi.org/10.4049/jimmunol.1201719>.
- [33] G.S. Garcia-Romo, S. Caielli, B. Vega, J. Connolly, F. Allantaz, Z. Xu, M. Punaro, J. Baisch, C. Guiducci, R.L. Coffman, F.J. Barrat, J. Banchereau, V. Pascual, Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus, *Sci. Transl. Med.* 3 (2011), <https://doi.org/10.1126/scitranslmed.3001201>.
- [34] R. Lande, D. Ganguly, V. Facchinetti, L. Frasca, C. Conrad, J. Gregorio, S. Meller, G. Chamilos, R. Sebasigari, V. Ricciari, R. Bassett, H. Amuro, S. Fukuhara, T. Ito, Y.J. Liu, M. Gilliet, Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA peptide complexes in systemic lupus erythematosus, *Sci. Transl. Med.* 3 (2011), <https://doi.org/10.1126/scitranslmed.3001180> 73ra19-73ra19.
- [35] A. Hakkim, B.G. Fürnrohr, K. Amann, B. Laube, U.A. Abed, V. Brinkmann, M. Herrmann, R.E. Voll, A. Zychlinsky, Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis, *Proc. Natl. Acad. Sci. U. S. A.* 107 (2010) 9813–9818 <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20439745&retmode=ref&cmd=prlinks>.
- [36] J. Leffler, K. Ciacma, B. Gullstrand, A.A. Bengtsson, M. Martin, A.M. Blom, A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources, *Arthritis Res. Ther.* 17 (2015) 205, <https://doi.org/10.1186/s13075-015-0726-y>.
- [37] L. a Casciola-Rosen, G. Anhalt, a Rosen, Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes, *J. Exp. Med.* 179 (1994) 1317–1330, <https://doi.org/10.1084/jem.179.4.1317>.
- [38] L. Casciola-Rosen, A. Rosen, M. Petri, M. Schlissel, Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus, *Proc. Natl. Acad. Sci. U. S. A.* 93 (1996) 1624–1629, <https://doi.org/10.1073/pnas.93.4.1624>.
- [39] P. Lehmann, B. Homey, Clinic and pathophysiology of photosensitivity in lupus erythematosus, *Autoimmun. Rev.* 8 (2009) 456–461, <https://doi.org/10.1016/j.autrev.2008.12.012>.
- [40] C. Guiducci, M. Gong, Z. Xu, M. Gill, D. Chaussabel, T. Meeker, J.H. Chan, T. Wright, M. Punaro, S. Bolland, V. Soumelis, J. Banchereau, R.L. Coffman, V. Pascual, F.J. Barrat, TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus, *Nature* 465 (2010) 937–941, <https://doi.org/10.1038/nature09102>.
- [41] H. Paidassi, P. Tacnet-Delorme, V. Garlatti, C. Darnault, B. Ghebrehiwet, C. Gaboriaud, G.J. Arlaud, P. Frachet, C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition, *J. Immunol.* 180 (2008) 2329–2338, <https://doi.org/10.4049/jimmunol.180.4.2329>.
- [42] M.R. Ehrenstein, C.A. Notley, The importance of natural IgM: scavenger, protector and regulator, *Nat. Rev. Immunol.* 10 (2010) 778–786, <https://doi.org/10.1038/nri2849>.
- [43] R.A. Thompson, M. Haeny, K.B.M. Reid, J.G. Davies, R.H.R. White, A.H. Cameron, A genetic defect of the C1q subcomponent of complement associated with childhood (immune complex) nephritis, *N. Engl. J. Med.* 303 (1980) 22–24, <https://doi.org/10.1056/NEJM198007033030107>.
- [44] V. Sisirak, B. Sally, V. D'Agati, V. Martinez-Ortiz, Z.B. Özçakar, J. David, A. Rashidfarrokhi, A. Yeste, C. Panea, A.S.S. Chida, M. Bogunovic, I.L.I. Ivanov, F.J.J. Quintana, I. Sanz, K.B.B. Elkon, M. Tekin, F. Yalçınkaya, T.J.J. Cardozo, R.M.M. Clancy, J.P.P. Buyon, B. Reizis, Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity, *Cell* 166 (2016) 88–101, <https://doi.org/10.1016/j.cell.2016.05.034>.
- [45] M.S. Lo, Monogenic lupus, *Curr. Rheumatol. Rep.* 18 (2016) 1–7, <https://doi.org/10.1007/s11926-016-0621-9>.
- [46] E.M. Tan, A.S. Cohen, J.F. Fries, A.T. Masi, D.J. Mcshane, N.F. Rothfield, J.G. Schaller, N. Talal, R.J. Winchester, The 1982 revised criteria for the classification of systemic lupus erythematosus, *Arthritis Rheum.* 25 (1982) 1271–1277, <https://doi.org/10.1002/art.1780251101>.
- [47] M.C. Hochberg, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, *Arthritis Rheum.* 40 (1997) 1725, [https://doi.org/10.1002/1529-0131\(199709\)40:9<1725::AID-ART29>3.0.CO;2-Y](https://doi.org/10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y).
- [48] M. Petri, A.-M. Orbai, G.S. Alarcón, et al., Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus, *Arthritis Rheum.* 64 (2012) 2677–2686, <https://doi.org/10.1002/art.34473.Derivation>.
- [49] S.K. Tedeschi, S.R. Johnson, D. Boumpas, D. Daikh, T. Dörner, D. Jayne, D. Kamen, K. Lerström, M. Mosca, R. Ramsey-Goldman, C. Sinnette, D. Wofsy, J.S. Smolen, R.P. Naden, M. Aringer, K.H. Costenbader, Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration, *Arthritis Care Res.* 70 (2018) 571–581, <https://doi.org/10.1002/acr.23317>.
- [50] M. Petri, D. Goldman, L.S. Magder, Validation of proposed EULAR/acr SLE classification criteria versus SLICC SLE classification criteria, *Arthr. Rheumatol.* 70 (suppl) (2018).
- [51] E.A.R. Hartman, A. van Royen-Kerkhof, J.W.G. Jacobs, P.M.J. Welsing, R.D.E. Fritsch-Stork, Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-an, *Autoimmun. Rev.* 17 (2018) 316–322, <https://doi.org/10.1016/j.autrev.2018.01.007>.
- [52] D. Wallace, B.H. Hahn, Dubois' Lupus Erythematosus and Related Syndromes, eighth ed., Saunders, 2012.
- [53] G.S. Firestein, R.C. Budd, S. Gabriel, I.B. McInnes, J. O'Dell, Kelley and Firestein's Textbook of Rheumatology, tenth ed., Elsevier, 2016.
- [54] E.Z. Hejazi, V.P. Werth, Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment, *Am. J. Clin. Dermatol.* 17 (2016) 135–146, <https://doi.org/10.1007/s40257-016-0173-9>.
- [55] H.W. Walling, R.D. Sontheimer, Cutaneous lupus erythematosus: issues in diagnosis and treatment, *Am. J. Clin. Dermatol.* 10 (2009) 365–381, <https://doi.org/10.2165/11310780-000000000-00000>.
- [56] T. Hasan, F. Nyberg, E. Stephansson, P. Puska, M. Hakkinen, S. Sarna, A.-M. Ros, A. Ranki, Photosensitivity in lupus erythematosus, UV photoprovocation results compared with history of photosensitivity and clinical findings, *Br. J. Dermatol.* 136 (1997) 699–705, <https://doi.org/10.1046/j.1365-2133.1997.6591644.x>.
- [57] C.J.G. Sanders, H. Van Weelden, G.A.A. Kazzaz, V. Sigurdsson, J. Toonstra, C.A.F.M. Bruijnzeel-Koomen, Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol, *Br. J. Dermatol.* 149 (2003) 131–137, <https://doi.org/10.2165/11591790-000000000-00000>.
- [58] A. Kuhn, M. Sonntag, D. Richter-Hintz, C. Oslislo, M. Megahed, T. Ruzicka, P. Lehmann, Phototesting in lupus erythematosus: a 15-year experience, *J. Am. Acad. Dermatol.* 45 (2001) 86–95, <https://doi.org/10.1067/mjd.2001.114589>.
- [59] G. Zandman-Goddard, M. Solomon, Z. Rosman, E. Peeva, Y. Shoenfeld, Environment and lupus-related diseases, *Lupus* 21 (2012) 241–250, <https://doi.org/10.1177/0961203311426568>.
- [60] D. Alarcón Segovia, J.A. Cetina, Lupus hair, *Am. J. Med. Sci.* 267 (1974) 241–242, <https://doi.org/10.1039/c5ra13683k>.
- [61] H.A. Miot, L.D.B. Miot, G.R. Haddad, Association between discoid lupus erythematosus and cigarette smoking: a case-control study, *Dermatology* 211 (2005) 118–122, <https://doi.org/10.1159/000086440>.
- [62] B.C. Böckle, N.T. Sepp, Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients, *Lupus* 24 (2015) 669–674, <https://doi.org/10.1177/0961203314559630>.
- [63] E.W. Piette, K.P. Foering, A.Y. Chang, J. Okawa, T.R. Ten Have, R. Feng, V.P. Werth, Impact of smoking in cutaneous lupus erythematosus, *Arch. Dermatol.* 148 (2012) 317–322, <https://doi.org/10.1001/archdermatol.2011.342>.
- [64] F. Chasset, C. Francès, S. Barete, Z. Amoura, L. Arnaud, Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature, *J. Am. Acad. Dermatol.* 72 (2015) 634–639, <https://doi.org/10.1016/j.jaad.2014.12.025>.
- [65] M. Petri, Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update, *Arthritis Care Res.* 8 (1995) 137–145 <http://www.ncbi.nlm.nih.gov/pubmed/7654797>.
- [66] J.M. Grossman, Lupus arthritis, *Best Pract. Res. Clin. Rheumatol.* 23 (2009) 495–506, <https://doi.org/10.1016/j.berh.2009.04.003>.
- [67] A. Budhram, R. Chu, S. Rusta-Sallehy, G. Ioannidis, J.A. Denburg, J.D. Adachi, D.A. Haaland, Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis, *Lupus* 23 (2015) 1156–1163, <https://doi.org/10.1177/0961203314540967>.
- [68] C.F. Lins, M.B. Santiago, Ultrasound evaluation of joints in systemic lupus erythematosus: a systematic review, *Eur. Radiol.* 25 (2015) 2688–2692, <https://doi.org/10.1007/s00330-015-3670-y>.
- [69] B. Ostendorf, A. Scherer, C. Specker, U. Mödder, M. Schneider, Jacoud's arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging, *Arthritis Rheum.* 48 (2003) 157–165, <https://doi.org/10.1002/art.10753>.
- [70] E.S. Zollars, M. Hyer, B. Wolf, R. Chapin, Measuring lupus arthritis activity using contrasted high-field MRI. Associations with clinical measures of disease activity and novel patterns of disease, *Lupus Sci. Med.* 5 (2018) e000264, <https://doi.org/10.1136/lupus-2018-000264>.
- [71] F. Wolfe, M. Petri, G.S. Alarcón, J. Goldman, E.F. Chakravarty, R.S. Katz, E.W. Karlson, Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity, *J. Rheumatol.* 36 (2008) 82–88, <https://doi.org/10.3899/jrheum.080212>.
- [72] M. Petri, M. Naqibuddin, K.A. Carson, D.J. Wallace, M.H. Weisman, S.L. Holliday, M. Sampedro, P.A. Padilla, R.L. Brey, Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus, *J. Rheumatol.* 37 (2010) 2032–2038, <https://doi.org/10.3899/jrheum.091366>.
- [73] H.M. Bastian, J.M. Roseman, G. Mcgwin, G.S. Alarcón, A.W. Friedman, B.J. Fessler, B.A. Baethge, J.D. Revell, Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis, *Lupus* 11 (2002) 152–160, <https://doi.org/10.1191/0961203302lu1580a>.
- [74] S. Bernatsky, J.F. Boivin, L. Joseph, S. Manzi, E. Ginzler, D.D. Gladman, M. Urowitz, P.R. Fortin, M. Petri, S. Barr, C. Gordon, S.C. Bae, D. Isenberg, A. Zoma, C. Aranow, M.A. Dooley, O. Nived, G. Sturfel, K. Steinsson, G. Alarcón, J.L. Nécal, M. Zummer, J. Hanly, S. Emsworth, J. Pope, S. Edworthy, A. Rahman, J. Sibley, H. El-Gabalawy, T. McCarthy, Y. St. Pierre, A. Clarke, R. Ramsey-Goldman, Mortality in systemic lupus erythematosus, *Arthritis Rheum.* 54 (2006) 2550–2557, <https://doi.org/10.1002/art.21955>.
- [75] M. Faurschou, H. Starklint, P. Halberg, S. Jacobsen, Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure, *J. Rheumatol.* 33 (2006) 1563–1569.

- [76] D. Wakasugi, T. Gono, Y. Kawaguchi, M. Hara, Y. Koseki, Y. Katsumata, M. Hanaoka, H. Yamanaka, Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures, *J. Rheumatol.* 39 (2012) 79–85, <https://doi.org/10.3899/jrheum.110532>.
- [77] L. Christopher-Stine, M. Siedner, J. Lin, M. Haas, H. Parekh, M. Petri, D.M. Fine, Renal biopsy in lupus patients with low levels of proteinuria, *J. Rheumatol.* 34 (2007) 332–335.
- [78] L. Christopher-Stine, M. Petri, B.C. Astor, D. Fine, Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis, *J. Rheumatol.* 31 (2004) 1557–1559 <http://www.ncbi.nlm.nih.gov/pubmed/15290735>.
- [79] S.W. Olson, J.J. Lee, L.K. Prince, T.P. Baker, P. Papadopoulos, J. Edison, K.C. Abbott, Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis, *Clin. J. Am. Soc. Nephrol.* 8 (2013) 1702–1708, <https://doi.org/10.2215/CJN.01910213>.
- [80] A.-M. Orbai, L. Truedsson, G. Sturfelt, O. Nived, H. Fang, G. Alarcón, C. Gordon, J. Merrill, P. Fortin, I. Bruce, D. Isenberg, D. Wallace, R. Ramsey-Goldman, S.-C. Bae, J. Hanly, J. Sanchez-Guerrero, A. Clarke, C. Aranow, S. Manzi, M. Urowitz, D. Gladman, K. Kalunian, M. Costner, V. Werth, A. Zoma, S. Bernatsky, G. Ruiz-Iratorza, M. Khamashta, S. Jacobsen, J. Buyon, P. Maddison, M. Dooley, R. Van Vollenhoven, E. Ginzler, T. Stoll, C. Peschken, J. Jorizzo, J. Callen, S. Lim, B. Fessler, M. Inanc, D. Kamen, A. Rahman, K. Steinsson, A. Franks, L. Sigler, S. Hameed, N. Pham, R. Brey, M. Weisman, G. McGwin, L. Magder, M. Petri, Anti-C1q antibodies in systemic lupus erythematosus, *Lupus* 24 (2014), <https://doi.org/10.1177/0961203314547791> pii: 0961203314547791.
- [81] E. Akhter, R. Burlingame, A. Seaman, L. Magder, M. Petri, Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers, *Lupus* 20 (2011) 1267–1274, <https://doi.org/10.1177/0961203311411597>.
- [82] G. Stojan, M. Petri, Anti-C1q in systemic lupus erythematosus, *Lupus* 25 (2016) 873–877, <https://doi.org/10.1177/0961203316645205>.
- [83] J.J. Weening, V.D. D'agati, M.M. Schwartz, S.V. Seshan, C.E. Alpers, G.B. Appel, J.E. Balow, J.A.N.A. Brujin, T. Cook, F. Ferrario, A.B. Fogo, E.M. Ginzler, L.E.E. Hebert, G. Hill, P. Hill, J.C. Jennette, N.C. Kong, P. Lesavre, M. Lockshin, L.-M. Looi, H. Makino, L.A. Moura, M. Nagata, The classification of glomerulonephritis in systemic lupus erythematosus revisited, *Kidney Int.* 65 (2004) 521–530, <https://doi.org/10.1111/j.1523-1755.2004.00443.x>.
- [84] P. Shea-Simonds, T.D. Cairns, C. Roufosse, T. Cook, T.J. Vyse, Lupus podocytopathy, *Rheumatology* 48 (2009) 1616–1618, <https://doi.org/10.1093/rheumatology/kep256>.
- [85] E. Descombes, D. Droz, L. Drouet, J.P. Grünfeld, P. Lesavre, Renal vascular lesions in lupus nephritis, *Medicine (Baltimore)* 76 (1997) 355–368 <http://www.ncbi.nlm.nih.gov/pubmed/9352738>.
- [86] S.P. Salvatore, L.M.C. Barisoni, A.M. Herzenberg, P.N. Chander, V. Nickleleit, S.V. Seshan, Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or Lupus-like disease, *Clin. J. Am. Soc. Nephrol.* 7 (2012) 914–925, <https://doi.org/10.2215/CJN.11751111>.
- [87] H. Ainiala, A. Hietaharju, J. Loukkola, J. Peltola, M. Korpela, R. Metsänoja, A. Auvinen, Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation, *Arthritis Rheum.* 45 (2001) 419–423, <https://doi.org/10.1016/j.measurement.2013.09.007>.
- [88] M. Petri, A.M. Orbai, G.S. Alarcón, C. Gordon, J.T. Merrill, P.R. Fortin, I.N. Bruce, D. Isenberg, D.J. Wallace, O. Nived, G. Sturfelt, R. Ramsey-Goldman, S.C. Bae, J.G. Hanly, J. Sánchez-Guerrero, A. Clarke, C. Aranow, S. Manzi, M. Urowitz, D. Gladman, K. Kalunian, M. Costner, V.P. Werth, A. Zoma, S. Bernatsky, G. Ruiz-Iratorza, M.A. Khamashta, S. Jacobsen, J.P. Buyon, P. Maddison, M.A. Dooley, R.F. Van Vollenhoven, E. Ginzler, T. Stoll, C. Peschken, J.L. Jorizzo, J.P. Callen, S.S. Lim, B.J. Fessler, M. Inanc, D.L. Kamen, A. Rahman, K. Steinsson, A.G. Franks, L. Sigler, S. Hameed, H. Fang, N. Pham, R. Brey, M.H. Weisman, G. McGwin, L.S. Magder, Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus, *Arthritis Rheum.* 64 (2012) 2677–2686, <https://doi.org/10.1002/art.34473>.
- [89] W.L. Sibbitt, R.R. Sibbitt, W.M. Brooks, Neuroimaging in neuropsychiatric systemic lupus erythematosus, *Arthritis Rheum.* 42 (1999) 2026–2038, [https://doi.org/10.1002/1529-0131\(199910\)42:10<2026::AID-ANR2>3.0.CO;2-J](https://doi.org/10.1002/1529-0131(199910)42:10<2026::AID-ANR2>3.0.CO;2-J).
- [90] J. Birnbaum, M. Petri, R. Thompson, I. Izbudak, D. Kerr, Distinct subtypes of myelitis in systemic lupus erythematosus, *Arthritis Rheum.* 60 (2009) 3378–3387, <https://doi.org/10.1002/art.24937>.
- [91] D.H. Miller, N. Buchanan, G. Barker, S.P. Morrissey, B.E. Kendall, P. Rudge, M. Khamashta, G.R. Hughes, W.I. McDonald, Gadolinium-enhanced magnetic resonance imaging of the central nervous system in systemic lupus erythematosus, *J. Neurol.* 239 (1992) 460–464 <https://doi.org/10.1007/BF00380615>.
- [92] W.L. Sibbitt, W.M. Brooks, L.J. Haseler, R.H. Griffey, L.M. Frank, B.L. Hart, R.R. Sibbitt, Spin-spin relaxation of brain tissues in systemic lupus erythematosus, *Arthritis Rheum.* 38 (1995) 810–818, <https://doi.org/10.1002/art.1780380615>.
- [93] S.G. West, W. Emlen, M.H. Wener, B.L. Kotzin, Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests, *Am. J. Med.* 99 (1995) 153–163, [https://doi.org/10.1016/S0002-9343\(99\)80135-1](https://doi.org/10.1016/S0002-9343(99)80135-1).
- [94] R.M. Carbotte, S.D. Denburg, J.A. Denburg, Prevalence of cognitive impairment in systemic lupus erythematosus, *J. Nerv. Ment. Dis.* 174 (1986) 357–364 <http://www.ncbi.nlm.nih.gov/pubmed/3711879>.
- [95] E. Kozora, M.C. Ellison, S. West, Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus, *Arthritis Care Res.* 51 (2004) 810–818, <https://doi.org/10.1002/art.20692>.
- [96] M. Petri, M. Naqibuddin, K.A. Carson, M. Sampedro, D.J. Wallace, M.H. Weisman, S.L. Holliday, P.A. Padilla, R.L. Brey, Cognitive function in a systemic lupus erythematosus inception cohort, *J. Rheumatol.* 35 (2008) 1776–1781 <https://doi.org/10.1007/10136/ard.2008.101766>.
- [97] M. Petri, M. Naqibuddin, K.A. Carson, D.J. Wallace, M.H. Weisman, S.L. Holliday, M. Sampedro, P.A. Padilla, R.L. Brey, Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus, *J. Rheumatol.* 37 (2010) 2032–2038, <https://doi.org/10.3899/jrheum.091366>.
- [98] E.A. Leadbetter, I.R. Rifkin, A.M. Hohlbaum, B.C. Beaudette, M.J. Shlomchik, A. Marshak-Rothstein, Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors, *Nature* 416 (2002) 603–607, <https://doi.org/10.1038/416603a>.
- [99] T.K. Means, E. Latz, F. Hayashi, M.R. Murali, D.T. Golenbock, A.D. Luster, Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9, *J. Clin. Invest.* 115 (2005) 407–417, <https://doi.org/10.1172/JCI23025>.
- [100] A. Kuznik, M. Bencina, U. Svajcar, M. Jeras, B. Rozman, R. Jerala, Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines, *J. Immunol.* 186 (2011) 4794–4804, <https://doi.org/10.4049/jimmunol.1000702>.
- [101] R. Lafyatis, M. York, A. Marshak-Rothstein, Antimalarial agents: closing the gate on toll-like receptors? *Arthritis Rheum.* 54 (2006) 3068–3070, <https://doi.org/10.1002/art.22157>.
- [102] M. Petri, Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis, *Lupus* 5 (Suppl 1) (1996) S16–S22 <http://www.ncbi.nlm.nih.gov/pubmed/8803905>.
- [103] R. Fox, Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development, *Lupus* 5 (Suppl 1) (1996) S4–S10 <http://www.ncbi.nlm.nih.gov/pubmed/8803903>.
- [104] A. Wozniacka, A. Lesiak, J. Narbutt, D.P. McCauliffe, A. Sysa-Jedrzejowska, Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients, *Lupus* 15 (2006) 268–275, <https://doi.org/10.1191/0961203306lu22990a>.
- [105] J. An, J.J. Woodward, T. Sasaki, M. Minie, K.B. Elkou, Cutting edge: antimalarial drugs inhibit IFN- β production through blockade of cyclic GMP-AMP synthase-DNA interaction, *J. Immunol.* 194 (2015) 4089–4093, <https://doi.org/10.10049/jimmunol.1402793>.
- [106] G.S. Alarcón, G. McGwin, A.M. Bertoli, B.J. Fessler, J. Calvo-Alén, H.M. Bastian, L.M. Vilá, J.D. Reveille, Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L), *Ann. Rheum. Dis.* 66 (2007) 1168–1172, <https://doi.org/10.1136/ard.2006.068676>.
- [107] G. Ruiz-Iratorza, M.-V. Egurbe, J.-I. Pijoan, M. Garmendia, I. Villar, A. Martínez-Berriotxo, J.-G. Erdozain, C. Aguirre, Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus, *Lupus* 15 (2006) 577–583, <https://doi.org/10.1177/0961203306071872>.
- [108] G. Ruiz-Iratorza, M. Ramos-Casals, P. Brito-Zeron, M.A. Khamashta, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, *Ann. Rheum. Dis.* 69 (2010) 20–28, <https://doi.org/10.1136/ard.2008.101766>.
- [109] C.C. Mok, S.M. Tse, K.L. Chan, L.Y. Ho, Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort, *Lupus* 27 (2018) 722–727, <https://doi.org/10.1177/0961203317739129>.
- [110] Canadian Hydroxychloroquine Study Group, A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus, *N. Engl. J. Med.* 324 (1991) 150–154, <https://doi.org/10.1056/NEJM199101173240303>.
- [111] B.J. Fessler, G.S. Alarcón, G. McGwin, J. Roseman, H.M. Bastian, A.W. Friedman, B.A. Baethge, L. Vilá, J.D. Reveille, Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual, *Arthritis Rheum.* 52 (2005) 1473–1480, <https://doi.org/10.1002/art.21039>.
- [112] S. Fasano, L. Pierro, I. Pantano, M. Iudici, G. Valentini, Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus, *J. Rheumatol.* 44 (2017) 1032–1038, <https://doi.org/10.3899/jrheum.161351>.
- [113] N. Kasitanon, D.M. Fine, M. Haas, L.S. Magder, M. Petri, Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis, *Lupus* 15 (2006) 366–370, <https://doi.org/10.1191/0961203306lu23130a>.
- [114] J.G. Hanly, M.B. Urowitz, L. Su, C. Gordon, S.-C. Bae, J. Sanchez-Guerrero, J. Romero-Diaz, D.J. Wallace, A.E. Clarke, E. Ginzler, J.T. Merrill, D.A. Isenberg, A. Rahman, M. Petri, P.R. Fortin, D. Gladman, I.N. Bruce, K. Steinsson, M. Dooley, M.A. Khamashta, G.S. Alarcón, B.J. Fessler, R. Ramsey-Goldman, S. Manzi, A.A. Zoma, G.K. Sturfelt, O. Nived, C. Aranow, M. Mackay, M. Ramos-Casals, R. van Vollenhoven, K.C. Kalunian, G. Ruiz-Iratorza, S. Lim, D.L. Kamen, C.A. Peschken, M. Inanc, C. Theriault, K. Thompson, V. Farewell, Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study, *Ann. Rheum. Dis.* 71 (2012) 1502–1509, <https://doi.org/10.1136/annrheumdis-2011-201089>.
- [115] R.M. Andrade, G.S. Alarcón, L.A. González, M. Fernández, M. Apte, L.M. Vilá, G. McGwin, J.D. Reveille, Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV), *Ann. Rheum. Dis.* 67 (2008) 829–834, <https://doi.org/10.1136/ard.2007.077594>.
- [116] L.A. González, G.J. Pons-Estel, J. Zhang, L.M. Vilá, J.D. Reveille, G.S. Alarcón, Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic

- lupus cohort, *Lupus* 18 (2009) 822–830, <https://doi.org/10.1177/0961203309104392>.
- [117] T. Ruzicka, C. Sommerberg, G. Goerz, P. Kind, H. Mensing, Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine, *Br. J. Dermatol.* 127 (1992) 513–518 <http://www.ncbi.nlm.nih.gov/pubmed/1467292>.
- [118] A. Kuhn, V. Ruland, G. Bonsmann, Cutaneous lupus erythematosus: update of therapeutic options: Part I, *J. Am. Acad. Dermatol.* 65 (2011) e179–e193, <https://doi.org/10.1016/j.jaad.2010.06.018>.
- [119] H.J. Williams, M.J. Egger, J.Z. Singer, R.F. Willkens, K.C. Kalunian, D.O. Clegg, J.L. Skosey, R.H. Brooks, G.S. Alarcón, V.D. Steen, Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus, *J. Rheumatol.* 21 (1994) 1457–1462 <http://www.ncbi.nlm.nih.gov/pubmed/7983646>.
- [120] H. Babary, X. Liu, Y. Ayatollahi, X.P. Chen, L. Doo, L.K. Uppaluru, M.K. Kwak, C. Kulaga, D. Modjinou, E. Olech, J.W. Yoo, Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: a systematic review and meta-analysis, *Int. J. Rheum. Dis.* 21 (2018) 84–92, <https://doi.org/10.1111/1756-185X.13159>.
- [121] M. Petri, C. Lakatta, L. Magder, D. Goldman, Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis, *Am. J. Med.* 96 (1994) 254–259, [https://doi.org/10.1016/0002-9343\(94\)90151-1](https://doi.org/10.1016/0002-9343(94)90151-1).
- [122] E. Cairoli, M. Rebella, N. Danese, V. Garra, E.F. Borba, Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect, *Lupus* 21 (2012) 1178–1182, <https://doi.org/10.1177/0961203312450084>.
- [123] M.C.M. Wasko, C.K. McClure, S.F. Kelsey, K. Huber, T. Orchard, F.G.S. Toledo, Antidiabetic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial, *Diabetologia* 58 (2015) 2336–2343, <https://doi.org/10.1007/s00125-015-3689-2>.
- [124] M. Petri, Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective, *Scand. J. Rheumatol.* 25 (1996) 191–193 <http://www.ncbi.nlm.nih.gov/pubmed/8792794>.
- [125] S.S. Pierangeli, E.N. Harris, In vivo models of thrombosis for the antiphospholipid syndrome, *Lupus* 5 (1996) 451–455, <https://doi.org/10.1177/096120339600500524>.
- [126] C.C. Mok, A. Mak, K.M. Ma, Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus, *Lupus* 14 (2005) 106–112, <https://doi.org/10.1191/0961203305lu2039oa>.
- [127] L.J. Herrinton, L. Liu, R. Goldfien, M.A. Michaels, T.N. Tran, Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimicrobials, *J. Rheumatol.* 43 (2016) 1503–1509, <https://doi.org/10.3899/jrheum.150671>.
- [128] Y. Fang, Y. Chen, T. Chung, L. See, K. Yu, S. Luo, C. Kuo, J. Lai, Hydroxychloroquine and risk of cancer in patients with primary Sjögren syndrome: propensity score matched landmark analysis, *Oncotarget* 8 (2017) 80461–80471, <https://doi.org/10.18632/oncotarget.19057>.
- [129] F. Wolfe, M.F. Marmor, Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus, *Arthritis Care Res. (Hoboken)* 62 (2010) 775–784, <https://doi.org/10.1002/acr.20133>.
- [130] M.F. Marmor, U. Kellner, T.Y.Y. Lai, J.S. Lyons, W.F. Mieler, American Academy of Ophthalmology, Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy, *Ophthalmology* 118 (2011) 415–422, <https://doi.org/10.1016/j.ophtha.2010.11.017>.
- [131] Y. Wang, J. Zhu, H.F. DeLuca, Where is the vitamin D receptor? *Arch. Biochem. Biophys.* 523 (2012) 123–133, <https://doi.org/10.1016/j.abb.2012.04.001>.
- [132] C. Daniel, N.A. Sartory, N. Zahn, H.H. Radeke, J.M. Stein, Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile, *J. Pharmacol. Exp. Ther.* 324 (2008) 23–33, <https://doi.org/10.1124/jpet.107.127209>.
- [133] S. Yu, M.T. Cantorina, The vitamin D receptor is required for iNKT cell development, *Proc. Natl. Acad. Sci. U. S. A.* 105 (2008) 5207–5212, <https://doi.org/10.1073/pnas.0711558105>.
- [134] J. V Bonventre, Antifibrotic vitamin D analogs, 123 (2013) 22–25, <https://doi.org/10.1172/JCI72748.4570>.
- [135] E. Der, H. Suryawanshi, S. Ranabothu, B. Goilav, H.M. Belmont, P. Izmirlly, N. Bornkamp, N. Jordan, T. Wang, M. Wu, J. James, J. Guthridge, S. Raychaudhuri, T. Tuschl, J. Buyon, C. Putterman, Kidney and skin single-cell RNA sequencing in lupus nephritis provides mechanistic insights and novel potential biomarkers, *Arthr. Rheumatol.* 69 (suppl) (2017), <https://acrabstracts.org/abstract/kidney-and-skin-single-cell-rna-sequencing-in-lupus-nephritis-provides-mechanistic-insights-and-novel-potential-biomarkers/>.
- [136] Y. Shi, T. Liu, L. Yao, Y. Xing, X. Zhao, J. Fu, X. Xue, Chronic Vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system, *Sci. Rep.* 7 (2017) 1, <https://doi.org/10.1038/s41598-017-03474-6>.
- [137] G. Ruiz-irastorza, M.V. Egurbide, N. Olivares, A. Martinez-Berriotoxa, C. Aguirre, Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences, *Rheumatology* 47 (2008) 920–923, <https://doi.org/10.1093/rheumatology/ken121>.
- [138] C.Y. Yang, P.S.C. Leung, I.E. Adamopoulos, M.E. Gershwin, The implication of vitamin D and autoimmunity: a comprehensive review, *Clin. Rev. Allergy Immunol.* 45 (2013) 217–226, <https://doi.org/10.1007/s12016-013-8361-3>.
- [139] C.C. Mok, Vitamin D and systemic lupus erythematosus: an update, *Expert Rev. Clin. Immunol.* 9 (2013) 453–463, <https://doi.org/10.1586/eci.13.19>.
- [140] H. Amital, Z. Szekanecz, G. Szücs, K. Dankó, E. Nagy, T. Csépany, E. Kiss, J. Rovensky, A. Tuchynova, D. Kozakova, A. Doria, N. Corrocher, N. Agmon-Levin, V. Barak, H. Orbach, G. Zandman-Goddard, Y. Shoenfeld, Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? *Ann. Rheum. Dis.* 69 (2010) 1155–1157, <https://doi.org/10.1136/ard.2009.120329>.
- [141] L. Andreoli, S. Piantoni, F. Dall'Ara, F. Allegri, P.L. Meroni, A. Tincani, Vitamin D and antiphospholipid syndrome, *Lupus* 21 (2012) 736–740, <https://doi.org/10.1177/0961203312446386>.
- [142] S. Piantoni, L. Andreoli, F. Allegri, P.L. Meroni, A. Tincani, Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease, *Rheumatism* 64 (2012) 307–313, <https://doi.org/10.4081/rheumatismo.2012.307>.
- [143] M. Petri, K.J. Bello, H. Fang, L.S. Magder, Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio, *Arthritis Rheum.* 65 (2013) 1865–1871, <https://doi.org/10.1002/art.37953>.
- [144] G.L. Lima, J. Paupitz, N.E. Aikawa, L. Takayama, E. Bonfa, R.M.R. Pereira, Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial, *Arthritis Care Res. (Hoboken)* 68 (2016) 91–98, <https://doi.org/10.1002/acr.22621>.
- [145] L. Durcan, M. Petri, Immunomodulators in SLE: clinical evidence and immunologic actions, *J. Autoimmun.* 74 (2016) 73–84, <https://doi.org/10.1016/j.jaut.2016.06.010>.
- [146] F. Labrie, A. Bélanger, J. Simard, Van Luu-The, C. Labrie, DHEA and peripheral androgen and estrogen formation: intracrinology, *Ann. N. Y. Acad. Sci.* 774 (1995) 16–28, <https://doi.org/10.1111/j.1749-6632.1995.tb17369.x>.
- [147] R.W. McMurray, W. May, Sex hormones and systemic lupus erythematosus: review and meta-analysis, *Arthritis Rheum.* 48 (2003) 2100–2110, <https://doi.org/10.1002/art.11105>.
- [148] R.G. Lahita, H.L. Bradlow, E. Ginzler, S. Pang, M. New, Low plasma androgens in women with systemic lupus erythematosus, *Arthritis Rheum.* 30 (1987) 241–248 <http://www.ncbi.nlm.nih.gov/pubmed/3032210>.
- [149] J.A. Lucas, S.A. Ahmed, M.L. Casey, P.C. MacDonald, Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice fed dehydroisoandrosterone, *J. Clin. Invest.* 75 (1985) 2091–2093, <https://doi.org/10.1172/JCI111929>.
- [150] D.M. Chang, S.J. Chu, H.C. Chen, S.Y. Kuo, J.H. Lai, Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus, *Ann. Rheum. Dis.* 63 (2004) 1623–1626, <https://doi.org/10.1136/ard.2003.016576>.
- [151] C.C.G. Chen, C.R. Parker, Adrenal androgens and the immune system, *Semin. Reprod. Med.* 22 (2004) 369–377, <https://doi.org/10.1055/s-2004-861553>.
- [152] J.S. Dillon, Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders, *Curr. Drug Targets Inflamm. Allergy* 4 (2005) 377–385 <http://www.ncbi.nlm.nih.gov/pubmed/16101547>.
- [153] M.A. Petri, R.G. Lahita, R.F. Van Vollenhoven, J.T. Merrill, M. Schiff, E.M. Ginzler, V. Strand, A. Kunz, K.J. Gorelick, K.E. Schwartz, Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial, *Arthritis Rheum.* 46 (2002) 1820–1829, <https://doi.org/10.1002/art.10364>.
- [154] J. Sanchez-Guerrero, H.E. Fragoso-Loyo, C.M. Neuwelt, D.J. Wallace, E.M. Ginzler, Y.R.S. Sherrer, H.H. McIlwain, P.G. Freeman, C. Arano, M.A. Petri, A.A. Deodhar, E. Blanton, S. Manzi, A. Kavanagh, J.R. Lisse, R. Ramsey-Goldman, J.D. McKay, A.J. Kivitz, P.J. Mease, A.E. Winkler, L.E. Kahl, A.H. Lee, R.A. Furie, C.V. Strand, L. Lou, M. Ahmed, B. Quarles, K.E. Schwartz, Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy, *J. Rheumatol.* 35 (2008) 1567–1575.
- [155] D.W. Cain, J.A. Cidlowski, Immune regulation by glucocorticoids, *Nat. Rev. Immunol.* 17 (2017) 233–247, <https://doi.org/10.1038/nri.2017.1>.
- [156] B.H. Hahn, M.A. McMahon, A. Wilkinson, W.D. Wallace, D.I. Daikh, J.D. Fitzgerald, G.A. Karpouzias, J.T. Merrill, D.J. Wallace, J. Yazdany, R. Ramsey-Goldman, K. Singh, M. Khalighi, S.I. Choi, M. Gogia, S. Kafaja, M. Kamgar, C. Lau, W.J. Martin, S. Parikh, J. Peng, A. Rastogi, W. Chen, J.M. Grossman, American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, *Arthritis Care Res.* 64 (2012) 797–808, <https://doi.org/10.1002/acr.21664>.
- [157] G.K. Bertsiaris, M. Tektonidou, Z. Amoura, M. Aringer, I. Bajema, J.H.M. Berden, J. Boletis, R. Cervera, T. Dörner, A. Doria, F. Ferrario, J. Floege, F.A. Houssiau, J.P.A. Ioannidis, D.A. Isenberg, C.G.M. Kallenberg, L. Lightstone, S.D. Marks, A. Martini, G. Moroni, I. Neumann, M. Praga, M. Schneider, A. Starra, V. Tesar, C. Vasconcelos, R.F. Van Vollenhoven, H. Zakharova, M. Haubitz, C. Gordon, D. Jayne, D.T. Boumpas, Joint European League Against Rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis, *Ann. Rheum. Dis.* 71 (2012) 1771–1782, <https://doi.org/10.1136/annrheumdis-2012-201940>.
- [158] M.B. Condon, D. Ashby, R.J. Pepper, H.T. Cook, J.B. Levy, M. Griffith, T.D. Cairns, L. Lightstone, Prospective observational single-center cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids, *Ann. Rheum. Dis.* 72 (2013) 1280–1286, <https://doi.org/10.1136/annrheumdis-2012-202844>.
- [159] M. Dooley, W.I. Pendergraft, E. Ginzler, N. Olsen, J. Tumlin, B. Rovin, F. Houssiau, D. Wofsy, D. Isenberg, N. Solomons, R. Huizinga, Speed of remission with the use

- of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study [abstract], *Arthr. Rheumatol.* 68 (suppl) (2016), <https://acrabstracts.org/abstract/speed-of-remission-with-the-use-of-voclosporin-mmf-and-low-dose-steroids-results-of-a-global-lupus-nephritis-study/>.
- [160] J.A. Singh, A. Hossain, A. Kotb, A. Oliveira, A.S. Mudano, J. Grossman, K. Winthrop, G.A. Wells, Treatments for lupus nephritis: a systematic review and network metaanalysis, *J. Rheumatol.* 43 (2016) 1801–1815, <https://doi.org/10.3899/jrheum.160041>.
- [161] D.D. Gladman, M.B. Urowitz, P. Rahman, D. Ibañez, L.-S. Tam, Accrual of organ damage over time in patients with systemic lupus erythematosus, *J. Rheumatol.* 30 (2003) 1955–1959 <http://www.ncbi.nlm.nih.gov/pubmed/12966597>.
- [162] L.S. Magder, M. Petri, Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus, *Am. J. Epidemiol.* 176 (2012) 708–719, <https://doi.org/10.1093/aje/kws130>.
- [163] M. Thamer, M.A. Hernán, Y. Zhang, D. Cotter, M. Petri, Prednisone, lupus activity, and permanent organ damage, *J. Rheumatol.* 36 (2009) 560–564, <https://doi.org/10.3899/jrheum.080828>.
- [164] A. Zonana-Nacach, S.G. Barr, L.S. Magder, M. Petri, Damage in systemic lupus erythematosus and its association with corticosteroids, *Arthritis Rheum.* 43 (2000) 1801–1808, [https://doi.org/10.1002/1529-0131\(200008\)43:8<1801::AID-ANR16>3.0.CO;2-O](https://doi.org/10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O).
- [165] A. Danowski, L. Magder, M. Petri, Flares in Lupus: outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone, *J. Rheumatol.* 33 (2006) 57–60.
- [166] E.A. Frangou, G. Bertias, D.T. Boumpas, Cytotoxic-immunosuppressive drug treatment, in: G.C. Tsokos (Ed.), *Syst. Lupus Erythematosus Basic, Appl. Clin. Asp. Elsevier*, 2016.
- [167] A.D. Steinberg, J.L. Decker, A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis, *Arthritis Rheum.* 17 (1974) 923–937, <https://doi.org/10.1002/art.1780170602>.
- [168] H.A. Austin, J.H. Klippel, J.E. Balow, N.G.H. Le Riche, A.D. Steinberg, P.H. Plotz, J.L. Decker, Therapy of lupus nephritis, *N. Engl. J. Med.* 314 (1986) 614–619, <https://doi.org/10.1056/NEJM198603063141004>.
- [169] W.J. McCune, J. Golbus, W. Zeldes, P. Bohlke, R. Dunne, D.A. Fox, Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus, *N. Engl. J. Med.* 318 (1988) 1423–1431, <https://doi.org/10.1056/NEJM198806023182203>.
- [170] M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayama, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, T. Mimori, Y. Tanaka, Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system, *Ann. Rheum. Dis.* 66 (2007) 470–475, <https://doi.org/10.1136/ard.2006.057885>.
- [171] C. Magro-Checa, E.J. Zirkzee, T.W. Huizinga, G.M. Steup-Beekman, Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives, *Drugs* 76 (2016) 459–483, <https://doi.org/10.1007/s40265-015-0534-3>.
- [172] C.C. Mok, Con: cyclophosphamide for the treatment of lupus nephritis, *Nephrol. Dial. Transplant.* 31 (2016) 1053–1057, <https://doi.org/10.1093/ndt/gfw068>.
- [173] I. Tiede, G. Fritz, S. Strand, D. Poppe, R. Dvorsky, D. Strand, H.A. Lehr, S. Wirtz, C. Becker, R. Atreya, J. Mudter, K. Hildner, B. Bartsch, M. Holtmann, R. Blumberg, H. Walczak, H. Iven, P.R. Galle, M.R. Ahmadian, M.F. Neurath, CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes, *J. Clin. Invest.* 111 (2003) 1133–1145, <https://doi.org/10.1172/JCI200316432.Introduction>.
- [174] E. Ginzler, E. Sharon, H. Diamond, D. Kaplan, Long-term maintenance therapy with azathioprine in systemic lupus erythematosus, *Arthritis Rheum.* 18 (1975) 27–34 <http://www.ncbi.nlm.nih.gov/pubmed/1115745>.
- [175] M. Szejnbok, A. Stewart, H. Diamond, D. Kaplan, Azathioprine in the treatment of systemic lupus erythematosus. A controlled study, *Arthritis Rheum.* 14 (1971) 639–645.
- [176] C. Grootsholten, G. Ligtenberg, E.C. Hagen, A.W.L. Van Den Wall Bake, J.W. De Glas-Vos, M. Bijl, K.J. Assmann, J.A. Brujin, J.J. Weening, H.C. Van Houwelingen, R.H.W.M. Derksen, J.H.M. Berden, Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial, *Kidney Int.* 70 (2006) 732–742, <https://doi.org/10.1038/sj.ki.5001630>.
- [177] C. Grootsholten, I.M. Bajema, S. Florquin, E.J. Steenbergen, C.J. Peutz-Kootstra, R. Goldschmeding, M. Bijl, E.C. Hagen, H.C. Van Houwelingen, R.H.W.M. Derksen, J.H.M. Berden, Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis, *Arthritis Rheum.* 56 (2007) 924–937, <https://doi.org/10.1002/art.22449>.
- [178] M.A. Dooley, D. Jayne, E.M. Ginzler, D. Isenberg, N.J. Olsen, D. Wofsy, F. Eitner, G.B. Appel, G. Contreras, L. Lisk, N. Solomons, Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis, *N. Engl. J. Med.* 365 (2011) 1886–1895, <https://doi.org/10.1056/NEJMoa1014460>.
- [179] F.A. Houssiau, D. D'Cruc, S. Sangle, P. Remy, C. Vasconcelos, R. Petrovic, C. Fiehn, E.D.R. Garrido, I.M. Gilboe, M. Tektonidou, D. Blockmans, I. Ravelingien, V. Le Guern, G. Depresseux, L. Guillemin, R. Cervera, D. Abramowicz, F. Atzeni, M.G. Danielli, L. De Clercq, F. De Keyser, M. Delahousse, G. Espinosa, M. Golstein, M. Hirsch, A. Karras, P. Lang, M. Marchal, A. Marinho, R. Max, P. Peeters, P. Petera, T. Quémeneur, F. Raeman, P. Sarzi-Puttini, L.V. De Santis, L. Verresen, L. Weiss, R. Westhovens, Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial, *Ann. Rheum. Dis.* 69 (2010) 2083–2089, <https://doi.org/10.1136/ard.2010.131995>.
- [180] B. Griffiths, P. Emery, V. Ryan, D. Isenberg, M. Akil, R. Thompson, P. Maddison, I.D. Griffiths, A. Lorenzi, S. Miles, D. Situnayake, L.S. Teh, M. Plant, C. Hallengren, O. Nived, G. Sturfelt, K. Chakravarty, T. Tait, C. Gordon, The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE, *Rheumatology (Oxford)* 49 (2010) 723–732, <https://doi.org/10.1093/rheumatology/kep396>.
- [181] J. Ordi-Ros, L. Sáez-Comet, M. Pérez-Conesa, X. Vidal, F. Mitjavila, A. Castro Salomé, J. Cuquet Pedragosa, V. Ortiz-Santamaria, M. Mauri Plana, J. Cortés-Hernández, Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial, *Ann. Rheum. Dis.* 76 (2017) 1575–1582, <https://doi.org/10.1136/annrheumdis-2016-210882>.
- [182] A. Lateef, M. Petri, Systemic lupus erythematosus and pregnancy, *Rheum. Dis. Clin. N. Am.* 43 (2017) 215–226, <https://doi.org/10.1016/j.rdc.2016.12.009>.
- [183] N.K.H. De Boer, S.V.A. Jarbandhan, P. De Graaf, C.J.J. Mulder, R.M. Van Elburg, A.A. Van Bodegraven, Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites, *Am. J. Gastroenterol.* 101 (2006) 1390–1392, <https://doi.org/10.1111/j.1572-0241.2006.00538.x>.
- [184] P.M. Brown, A.G. Pratt, J.D. Isaacs, Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers, *Nat. Rev. Rheumatol.* 12 (2016) 731–742, <https://doi.org/10.1038/nrrheum.2016.175>.
- [185] P.A. Miescher, D. Riethmüller, Diagnosis and treatment of systemic lupus erythematosus, *Semin. Hematol.* 2 (1965) 1–28 <http://www.ncbi.nlm.nih.gov/pubmed/14268735>.
- [186] S.E. Sakthiwarthy R, Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy, *Lupus* 23 (3) (2014) 225–235 <http://www.ncbi.nlm.nih.gov/pubmed/14268735>.
- [187] P.R. Fortin, M. Abrahamowicz, D. Ferland, D. Laccaille, C.D. Smith, M. Zimmer, Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial, *Arthritis Rheum.* 59 (2008) 1796–1804, <https://doi.org/10.1002/art.24068>.
- [188] A. Allison, Mechanisms of action of mycophenolate mofetil, *Lupus* 14 (2005) 2–8, <https://doi.org/10.1191/0961203305LU21090A>.
- [189] T.M. Chan, F.K. Li, C.S.O. Tang, R.W.S. Wong, G.X. Fang, Y.L. Ji, C.S. Lau, A.K.M. Wong, M.K.L. Tong, K.W. Chan, K.N. Lai, Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis, *N. Engl. J. Med.* 343 (2000) 1156–1162, <https://doi.org/10.1056/NEJM200010193431604>.
- [190] E.M. Ginzler, M.A. Dooley, C. Aranon, M.Y. Kim, J. Buyon, J.T. Merrill, M. Petri, G.S. Gilkeson, D.J. Wallace, M.H. Weisman, G.B. Appel, Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis, *N. Engl. J. Med.* 353 (2005) 2219–2228, <https://doi.org/10.1056/NEJMoa043731>.
- [191] G.B. Appel, G. Contreras, M.A. Dooley, E.M. Ginzler, D. Isenberg, D. Jayne, L.-S. Li, E. Mysler, J. Sanchez-Guerrero, N. Solomons, D. Wofsy, Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis, *J. Am. Soc. Nephrol.* 20 (2009) 1103–1112, <https://doi.org/10.1681/ASN.2008101028>.
- [192] D.J. Tunncliffe, S.C. Palmer, L. Henderson, P. Masson, J.C. Craig, A. Tong, D. Singh-Grewal, R.S. Flanc, M.A. Roberts, A.C. Webster, G.F. Strippoli, Immunosuppressive treatment for proliferative lupus nephritis, *Cochrane Database Syst. Rev.* (2018), <https://doi.org/10.1002/14651858.CD002922.pub4>.
- [193] C.C. Mok, Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review, *Scand. J. Rheumatol.* 36 (2007) 329–337, <https://doi.org/10.1080/03009740701607042>.
- [194] E.M. Ginzler, D. Wofsy, D. Isenberg, C. Gordon, L. Lisk, M.A. Dooley, Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial, *Arthritis Rheum.* 62 (2010) 211–221, <https://doi.org/10.1002/art.25052>.
- [195] C.C. Mok, Calcineurin inhibitors in systemic lupus erythematosus, *Best Pract. Res. Clin. Rheumatol.* 31 (2017) 429–438, <https://doi.org/10.1016/j.berh.2017.09.010>.
- [196] Y. Ikezumi, K. Kanno, H. Koike, M. Tomita, M. Uchiyama, F. Shimizu, H. Kawachi, FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3, *Kidney Int.* 61 (2002) 1339–1350, <https://doi.org/10.1046/j.1523-1755.2002.00259.x>.
- [197] R. Liao, Q. Liu, Z. Zheng, J. Fan, W. Peng, Q. Kong, H. He, S. Yang, W. Chen, X. Tang, X. Yu, Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis, *PLoS One* 10 (2015) 1–16, <https://doi.org/10.1371/journal.pone.0132724>.
- [198] C. Faul, M. Donnelly, S. Merscher-Gomez, Y.H. Chang, S. Franz, J. Delfgaauw, J.M. Chang, H.Y. Choi, K.N. Campbell, K. Kim, J. Reiser, P. Mundel, The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A, *Nat. Med.* 14 (2008) 931–938, <https://doi.org/10.1038/nm.1857>.
- [199] B.K. Krämer, G. Montagnino, D. del Castillo, R. Margreiter, H. Sperschneider, C.J. Olbricht, B. Krüger, J. Ortuño, H. Köhler, U. Kuzendorf, H.K. Stammvoll, C.M. Taberner, F. Mühlbacher, M. Rivero, M. Arias, K.H. Dietl, D. del Castillo, J. Pascual, C. Olbricht, M. Kammerl, B. Krüger, K. Köhler, U. Sester, F. Mühlbacher, U. Kuzendorf, I. Hauser, C. Ponticelli, V. Bonomini, J.M. Taberner, M. Rivero, E. Ancona, G. Calconi, V. Cambi, G. la Greca, F. Mosca, F. Selvaggi, M. Meurisse, O. Detry, M. González Molina, G. Piccoli, M. Salvadori, M. Schilling, C. Raedelli, W. Arns, F. Suarez, G. Rodríguez Algarra, C. Asensio, R. Maiorca, G. Ancona, V. Sparacino, J.M. Morales, J.A. Gutierrez, R. Lauzurica, G.A. Verpooten, J. Sennesael, C. Heidecke, J. Garcia, L. Capdevila, D. Abendroth, G. Biesenbach, P. Altieri, G. Sorba, U. Valente, M. Castagneto, A. Purroy, P. Duhoux, C. Kremer, G. Stiegler, S. Schleibner, Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results, *Nephrol. Dial. Transplant.* 20 (2005) 968–973, <https://doi.org/10.1093/ndt/gfh739>.

- [200] X. Li, H. Ren, Q. Zhang, W. Zhang, X. Wu, Y. Xu, P. Shen, N. Chen, Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis, *Nephrol. Dial. Transplant.* 27 (2012) 1467–1472, <https://doi.org/10.1093/ndt/gfr484>.
- [201] W. Chen, X. Tang, Q. Liu, W. Chen, P. Fu, F. Liu, Y. Liao, Z. Yang, J. Zhang, J. Chen, T. Lou, J. Fu, Y. Kong, Z. Liu, A. Fan, S. Rao, Z. Li, X. Yu, Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial, *Am. J. Kidney Dis.* 57 (2011) 235–244, <https://doi.org/10.1053/j.ajkd.2010.08.036>.
- [202] J. Závada, S.S. Pešičková, R. Ryšavá, M. Olejárová, P. Horák, Z. Hrnčíř, I. Rychlík, M. Havrda, J. Vítová, J. Lukáč, J. Rovenský, D. Tegzova, J. Böhmová, J. Zdražil, J. Hána, C. Dostál, V. Tesar, Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study, *Lupus* 19 (2010) 1281–1289, <https://doi.org/10.1177/0961203310371155>.
- [203] J. Závada, S.S. Pešičková, R. Ryšavá, P. Horák, Z. Hrnčíř, J. Lukáč, J. Rovenský, J. Vítová, M. Havrda, I. Rychlík, J. Böhmová, V. Vlasáková, J. Slatinská, J. Zdražil, M. Olejárová, D. Tegzova, V. Tesar, Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A, *Lupus* 23 (2014) 69–74, <https://doi.org/10.1177/0961203313511555>.
- [204] J. Hannah, A. Casian, D. D'Crux, Tacrolimus use in lupus nephritis: a systematic review and meta-analysis, *Autoimmun. Rev.* 15 (2016) 93–101, <https://doi.org/10.1016/j.autrev.2015.09.006>.
- [205] C.C. Mok, K.Y. Ying, C.W. Yim, Y.P. Siu, K.H. Tong, C.H. To, W.L. Ng, Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up, *Ann. Rheum. Dis.* 75 (2016) 30–36, <https://doi.org/10.1136/annrheumdis-2014-206456>.
- [206] C.M. Lanata, T. Mahmood, D.M. Fine, M. Petri, Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis, *Lupus* 19 (2010) 935–940, <https://doi.org/10.1177/0961203310365714>.
- [207] J. Cortés-Hernández, M.T. Torres-Salido, A.S. Medrano, M.V. Tarrés, J. Ordi-Ros, Long-term outcomes - mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases, *Nephrol. Dial. Transplant.* 25 (2010) 3939–3948, <https://doi.org/10.1093/ndt/gfq322>.
- [208] C.C. Mok, C.H. To, K.L. Yu, L.Y. Ho, Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study, *Lupus* 22 (2013) 1135–1141, <https://doi.org/10.1177/0961203313502864>.
- [209] Z. Liu, H. Zhang, Z. Liu, C. Xing, P. Fu, Z. Ni, J. Chen, H. Lin, F. Liu, Y. He, Y. He, L. Miao, N. Chen, Y. Li, Y. Gu, W. Shi, W. Hu, Z. Liu, H. Bao, C. Zeng, M. Zhou, Multitarget therapy for induction treatment of lupus nephritis: a randomized trial, *Ann. Intern. Med.* 162 (2015) 18–26, <https://doi.org/10.7326/M14-1030>.
- [210] G. Moroni, A. Doria, M. Mosca, O.D.C. Alberighi, G. Ferraccioli, S. Todesco, C. Manno, P. Altieri, R. Ferrara, S. Greco, C. Ponticelli, A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years, *Clin. J. Am. Soc. Nephrol.* 1 (2006) 925–932, <https://doi.org/10.2215/CJN.02271205>.
- [211] W. Chen, Q. Liu, W. Chen, X. Tang, P. Fu, F. Liu, Y. Liao, Z. Yang, J. Zhang, J. Chen, T. Lou, J. Fu, Y. Kong, Z. Liu, Z. Li, X. Yu, Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial, *Lupus* 21 (2012) 944–952, <https://doi.org/10.1177/0961203312442259>.
- [212] J. Radhakrishnan, C.L. Kunis, V. D'Agati, G.B. Appel, Cyclosporine treatment of lupus membranous nephropathy, *Clin. Nephrol.* 42 (1994) 147–154 <http://www.ncbi.nlm.nih.gov/pubmed/7994932>.
- [213] D.Y. Yap, X. Yu, X.M. Chen, F. Lu, N. Chen, X.W. Li, C.S. Tang, T.M. Chan, Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome, *Nephrology* 17 (2012) 352–357, <https://doi.org/10.1111/j.1440-1797.2012.01574.x>.
- [214] D. Hallegua, D.J. Wallace, A.L. Metzger, R.Z. Rinaldi, J.R. Klinenberg, Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, *Lupus* 9 (2000) 241–251, <https://doi.org/10.1191/096120300680198935>.
- [215] H.A. Austin, G.G. Illei, M.J. Braun, J.E. Balow, Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy, *J. Am. Soc. Nephrol.* 20 (2009) 901–911, <https://doi.org/10.1681/ASN.2008060665>.
- [216] S. Busque, M. Cantarovich, S. Mulgaonkar, R. Gaston, A.O. Gaber, P.R. Mayo, S. Ling, R.B. Huizinga, H.U. Meier-Kriesche, The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de Novo kidney transplantation, *Am. J. Transplant.* 11 (2011) 2675–2684, <https://doi.org/10.1111/j.1600-6143.2011.03763.x>.
- [217] S. Parikh, W. Pendergraft, J. Tumlin, R. Saxena, N. Solomons, R. Huizinga, Treatment of active Lupus nephritis with Voclosporin: 48 week data from the auralv study, *Am. J. Kidney Dis. Conf. Natl. Kidney Found.* 69 (2017) A2, <https://doi.org/10.1053/j.ajkd.2017.03.005> 2017 Spring Clin. Meet. United States.
- [218] T. Cobo-Ibáñez, E. Loza-Santamaría, J.M. Pego-Reigosa, A.O. Marqués, Í. Rúa-Figueroa, A. Fernández-Nebro, R.C. Cáliz, F.J. López Longo, S. Muñoz-Fernández, Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review, *Semin. Arthritis Rheum.* 44 (2015) 175–185, <https://doi.org/10.1016/j.semarthrit.2014.04.002>.
- [219] L. Lan, F. Han, J. Chen, Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis, *J. Zhejiang Univ. Sci. B* 13 (2012) 731–744, <https://doi.org/10.1631/jzus.B1200057>.
- [220] J.T. Merrill, C.M. Neuwelt, D.J. Wallace, J.C. Shanahan, K.M. Latinis, J.C. Oates, T.O. Utset, C. Gordon, D.A. Isenberg, H.J. Hsieh, D. Zhang, P.G. Brunetta, Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial, *Arthritis Rheum.* 62 (2010) 222–233, <https://doi.org/10.1002/art.27233>.
- [221] B.H. Rovin, R. Furie, K. Latinis, R.J. Looney, F.C. Fervenza, J. Sanchez-Guerrero, R. Maciuga, D. Zhang, J.P. Garg, P. Brunetta, G. Appel, LUNAR Investigator Group, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study, *Arthritis Rheum.* 64 (2012) 1215–1226, <https://doi.org/10.1002/art.34359>.
- [222] R. John Looney, J. Anolik, I. Sanz, A perspective on B-cell-targeting therapy for SLE, *Mod. Rheumatol.* 20 (2010) 1–10, <https://doi.org/10.1007/s10165-009-0213-x>.
- [223] G. Cambridge, D.A. Isenberg, J.C.W. Edwards, M.J. Leandro, T.-S. Migone, M. Teodorescu, W. Stohl, B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, auto-antibody profile and clinical response, *Ann. Rheum. Dis.* 67 (2008) 1011–1016, <https://doi.org/10.1136/ard.2007.079418>.
- [224] M.R. Ehrenstein, C. Wing, The BAFFling effects of rituximab in lupus: danger ahead? *Nat. Rev. Rheumatol.* 12 (2016) 367–372, <https://doi.org/10.1038/nrrheum.2016.18>.
- [225] L.M. Carter, D.A. Isenberg, M.R. Ehrenstein, Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus, *Arthritis Rheum.* 65 (2013) 2672–2679, <https://doi.org/10.1002/art.38074>.
- [226] T. Kraaij, S.W.A. Kamerling, E.N.M. de Rooij, P.L.A. van Daele, O.W. Bredewold, J.A. Bakker, I.M. Bajema, H.U. Scherer, R.E.M. Toes, T.J.W. Huizinga, T.J. Rabelink, C. van Kooten, Y.K.O. Teng, The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus, *J. Autoimmun.* 91 (2018) 45–54, <https://doi.org/10.1016/j.jaut.2018.03.003>.
- [227] C. Aranow, M. Dall'Era, M. Byron, L. Ding, D. Smilek, B. Diamond, D. Wofsy, FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis, *Ann. Rheum. Dis.* 77 (2018) 690 LP-690 http://ard.bmj.com/content/77/Suppl_2/690.1.abstract.
- [228] F. MacKay, P. Schneider, Cracking the BAFF code, *Nat. Rev. Immunol.* 9 (2009) 491–502, <https://doi.org/10.1038/nri2572>.
- [229] J.F. Tremblay, Y. Hao, J.E. Stadanick, M.P. Cancro, The BlyS family: toward a molecular understanding of B cell homeostasis, *Cell Biochem. Biophys.* 53 (2009) 1–16, <https://doi.org/10.1007/s12013-008-9036-1>.
- [230] M.A. Petri, R.F. van Vollenhoven, J. Buyon, R.A. Levy, S.V. Navarra, R. Cervera, Z.J. Zhong, W.W. Freimuth, Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials, *Arthritis Rheum.* 65 (2013) 2143–2153, <https://doi.org/10.1002/art.37995>.
- [231] J.R. Groom, C.A. Fletcher, S.N. Walters, S.T. Grey, S.V. Watt, M.J. Sweet, M.J. Smyth, C.R. Mackay, F. Mackay, BAFF and MyD88 signals promote a lupus-like disease independent of T cells, *J. Exp. Med.* 204 (2007) 1959–1971, <https://doi.org/10.1084/jem.20062567>.
- [232] R. Furie, M. Petri, O. Zamani, R. Cervera, D.J. Wallace, D. Tegzová, J. Sanchez-Guerrero, A. Schwarting, J.T. Merrill, W.W. Chatham, W. Stohl, E.M. Ginzler, D.R. Hough, Z.J. Zhong, W. Freimuth, R.F. Van Vollenhoven, A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, *Arthritis Rheum.* 63 (2011) 3918–3930, <https://doi.org/10.1002/art.30613>.
- [233] S.V. Navarra, R.M. Guzmán, A.E. Gallacher, S. Hall, R.A. Levy, R.E. Jimenez, E.K.M. Li, M. Thomas, H.Y. Kim, M.G. León, G. Tanasescu, E. Nasonov, J.L. Lan, L. Pineda, Z.J. Zhong, W. Freimuth, M.A. Petri, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, *Lancet* 377 (2011) 721–731, [https://doi.org/10.1016/S0140-6736\(10\)61354-2](https://doi.org/10.1016/S0140-6736(10)61354-2).
- [234] R.F. Van Vollenhoven, M.A. Petri, R. Cervera, D.A. Roth, B.N. Ji, C.S. Kleoudis, Z.J. Zhong, W. Freimuth, Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response, *Ann. Rheum. Dis.* 71 (2012) 1343–1349, <https://doi.org/10.1136/annrheumdis-2011-200937>.
- [235] R. Furie, M. Khamashta, J.T. Merrill, V.P. Werth, K. Kalunian, P. Brohawn, G.G. Illei, J. Drappa, L. Wang, S. Yoo, Anifrolumab, an anti-interferon- α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus, *Arthr. Rheumatol.* 69 (2017) 376–386, <https://doi.org/10.1002/art.39962>.
- [236] AstraZeneca, Update on TULIP 1 Phase III Trial for Anifrolumab in Systemic Lupus Erythematosus, (n.d.). <https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html>.
- [237] X.O. Yang, A.D. Panopoulos, R. Nurieva, H.C. Seon, D. Wang, S.S. Watowich, C. Dong, STAT3 regulates cytokine-mediated generation of inflammatory helper T cells, *J. Biol. Chem.* 282 (2007) 9358–9363, <https://doi.org/10.1074/jbc.C600321200>.
- [238] C. Ma, D. Avery, A. Chan, M. Batten, J. Bustamante, S. Boisson-Dupuis, P. Arkwright, A. Kreins, D. Averbuch, D. Engelhard, K. Magdorf, S. Kilic, Y. Minogishi, S. Nonoyama, M. French, S. Choo, J. Smart, J. Peake, M. Wong, P. Gray, M. Cook, D. Fulcher, J.-L. Casanova, E. Deenick, S. Tangye, Functional STAT3 deficiency compromises the generation of human T follicular helper cells, *Blood* 119 (2012) 3997–4008, <https://doi.org/10.1182/blood-2011-11-392985> The.
- [239] H. Ueno, J. Banchereau, C.G. Vinuesa, Pathophysiology of T follicular helper cells in humans and mice, *Nat. Immunol.* 16 (2015) 142–152, <https://doi.org/10.1038/ni.3054>.

- [240] A.S. Shaltout, D. Sayed, M.S. Badary, A.M. Nafee, M.H. El Zohri, R. Bakry, S.H. Ahmed, Effect of IL6 and IL23 on double negative T cells and anti ds-DNA in systemic lupus erythematosus patients, *Hum. Immunol.* 77 (2016) 937–943, <https://doi.org/10.1016/j.humimm.2016.06.007>.
- [241] H. Dai, F. He, G.C. Tsokos, V.C. Kyttaris, IL-23 limits the production of IL-2 and promotes autoimmunity in lupus, *J. Immunol.* 199 (2017) 903–910, <https://doi.org/10.4049/jimmunol.1700418>.
- [242] R. van Vollenhoven, B. Hahn, G. Tsokos, C. Wagner, P. Lipsky, B. Hsu, M. Chevrier, R. Gordon, M. Triebel, S. Rose, S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study, *Lupus Sci. Med.* 5 (2018) A28 LP-A29 http://lupus.bmj.com/content/5/Suppl_1/A28.abstract.
- [243] M. Gadina, C. Johnson, D. Schwartz, M. Bonelli, S. Hasni, Y. Kanno, P. Changelian, A. Laurence, J.J. O'Shea, Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs, *J. Leukoc. Biol.* (2018) 1–16, <https://doi.org/10.1002/JLB.5R10218-084R>.
- [244] D.J. Wallace, R.A. Furie, Y. Tanaka, K.C. Kalunian, M. Mosca, M.A. Petri, T. Dörner, M.H. Cardiel, I.N. Bruce, E. Gomez, T. Carmack, A.M. DeLozier, J.M. Janes, M.D. Linnik, S. de Bono, M.E. Silk, R.W. Hoffman, Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial, *Lancet* 392 (2018) 222–231, [https://doi.org/10.1016/S0140-6736\(18\)31363-1](https://doi.org/10.1016/S0140-6736(18)31363-1).
- [245] M. Dall'Era, E. Chakravarty, D. Wallace, M. Genovese, M. Weisman, A. Kavanaugh, K. Kalunian, P. Dhar, E. Vincent, C. Pena-Rossi, D. Wofsy, N. Alum, A. Dubois, N. Kinman, M. Picard, A. Bortolotti, L. O'Grady, J. Hill, I. Nestorov, E. Salmon, Reduced B lymphocyte and immunoglobulin levels after atacept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial, *Arthritis Rheum.* 56 (2007) 4142–4150, <https://doi.org/10.1002/art.23047>.
- [246] J.T. Merrill, D.J. Wallace, S. Wax, A. Kao, P.A. Fraser, P. Chang, D. Isenberg, Efficacy and safety of atacept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study, *Arthr. Rheumatol.* 70 (2018) 266–276, <https://doi.org/10.1002/art.40360>.
- [247] D.J. Wallace, Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox, *Lupus* 17 (2008) 91–92, <https://doi.org/10.1177/0961203307086267>.
- [248] A. Kuhn, K. Gensch, M. Haust, A.M. Meuth, F. Boyer, P. Dupuy, P. Lehmann, D. Metz, T. Ruzicka, Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study, *J. Am. Acad. Dermatol.* 64 (2011) 37–48, <https://doi.org/10.1016/j.jaad.2009.12.053>.
- [249] F. Wolfe, M. Petri, G.S. Alarcón, J. Goldman, E.F. Chakravarty, R.S. Katz, E.W. Karlson, Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity, *J. Rheumatol.* 36 (2009) 82–88, <https://doi.org/10.3899/jrheum.080212>.
- [250] V. Torrente-Segarra, T.C. Salman-Monte, Iñigo Rúa-Figueroa, S. Pérez-Vicente, F.J. López-Longo, M. Galindo-Izquierdo, J. Calvo-Alén, A. Olivé-Marqués, J. Ibáñez-Ruán, L. Horcada, A. Sánchez-Atrio, C. Montilla, M. Rodríguez-Gómez, E. Díez-Álvarez, V. Martínez-Taboada, J.L. Andreu, O. Fernández-Berrizbeitia, J.A. Hernández-Beriain, M. Gantes, B. Hernández-Cruz, Ángela Pecondón-Español, C. Marras, G. Bonilla, J.M. Pego-Reigosa, R. Blanco, P. Vela-Casasempere, R. Melero-González, T. Otón-Sánchez, E. Tornero-Muriel, E. Uriarte-Isacelaya, M. Freire-González, M.C. Fito-Manteca, A. Fernández-Nebro, J. Narváez, A. Zea-Mendoza, J.C. Rosas-Gómez de Salazar, M. Ibáñez-Barceló, J.J. Pérez-Venegas, I. de la Torre Ortega, L.C. Pérez, P.C. Delgado, E. Rodríguez-Almaraz, E.S. Heredia, G.S. Soler, C.S. Ramírez, J.M. Senabre Gallego, M.A. Collado, J.A. Bernal, I.R. Vilamajó, A.J. Mas, C. Murillo, I.C. Barranco, E.G. Melchor, J.C. Fontova, M.G. Manrique, C.G. Lencastre, M.M. Martínez-Losa, R.M. Almagro, M.A. González-Gay Mantecón, I.P. Martiny, M. del Carmen Bejerano, I.V. Blanco, B. Moreira, E. Aurrecochea, T.R. Jimeno, ángeles A. Zamorano, C. Magro, E.R. Álvarez, C.E. Arruabarrena, M. ángeles A. Mérida, C.A. Egúes Dubuc, J.C. Fanlo, E.D. Álvarez, C. Vitovi, A.L. Robles, T.V. Rodríguez, M.V.I. Oyarzábal, M. ángeles, B. López, C.M. Romero Barco, J.A.M. López, O.S. Pernaute, T.G. de Vicuña Pinedo, M.V. Expósito, P.G. de la Peña, S.R. Rubio, J.J. González Martín, A.P. Gómez, C. Bohórquez, A.M. Hajkhan, A.I. Turrión Nieves, A.J. Lois Iglesias, A.L. Boteanu, M.L.G. Gamir, P.R. Alberti, S.M. Fernández, M.R. Oliva, C. Stoye, Iñigo H. Rodríguez, C.M. Rodríguez, B. de Aspe de la Iglesia, R.L. González, F.N. Sarabia, F.J. Toyos Sáenz de Miera, J.L.M. de la Fuente, J.U. Montañés, R.H. Sánchez, R.M. Pérez, B.R. Lozano, E. úcar Angulo, M.E.R. Lucea, L.L. Domínguez, J.J. Alegre Sancho, I. de La Morena Barrio, E. Valls, J.M. Ruiz, V.E. Quevedo Vila, S. Machín, J. Nóvoa, L.S. Fernández, Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus, *Clin. Exp. Rheumatol.* 34 (2016) 40–47.
- [251] C. Wang, C.H. Schmid, R. Rones, R. Kalish, J. Yin, D.L. Goldenberg, Y. Lee, T. McAlindon, A randomized trial of tai chi for fibromyalgia, *N. Engl. J. Med.* 363 (2010) 743–754, <https://doi.org/10.1056/NEJMoa0912611>.
- [252] F. Gomez-Pinilla, C. Hillman, The influence of exercise on cognitive abilities, *Compr. Physiol.* 3 (2013) 403–428, <https://doi.org/10.1002/cphy.c110063>.
- [253] C.M. Tench, J. McCarthy, I. McCurdie, P.D. White, D.P. D'Cruz, Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise, *Rheumatology (Oxford)* 42 (2003) 1050–1054, <https://doi.org/10.1093/rheumatology/keg289>.
- [254] M. Giannelou, C.P. Mavragani, Cardiovascular disease in systemic lupus erythematosus: a comprehensive update, *J. Autoimmun.* 82 (2017) 1–12, <https://doi.org/10.1016/j.jaut.2017.05.008>.
- [255] M. Petri, R. Roubenoff, G.E. Dallal, M.R. Nadeau, J. Selhub, I.H. Rosenberg, Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus, *Lancet* 348 (1996) 1120–1124, [https://doi.org/10.1016/S0140-6736\(96\)03032-2](https://doi.org/10.1016/S0140-6736(96)03032-2).
- [256] Homocysteine Studies Collaboration, Homocysteine and risk of ischemic heart disease and stroke, *JAMA* 288 (2002) 2015, <https://doi.org/10.1001/jama.288.16.2015>.
- [257] L.L. Humphrey, R. Fu, K. Rogers, M. Freeman, M. Helfand, Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis, *Mayo Clin. Proc.* 83 (2016) 1203–1212, <https://doi.org/10.4065/83.11.1203>.
- [258] V. Veeranna, S.K. Zalawadiya, A. Niraj, J. Pradhan, B. Ference, R.C. Burack, S. Jacob, L. Afonso, Homocysteine and reclassification of cardiovascular disease risk, *J. Am. Coll. Cardiol.* 58 (2011) 1025–1033, <https://doi.org/10.1016/j.jacc.2011.05.028>.
- [259] F. Yi, E.A. Dos Santos, M. Xia, Q.Z. Chen, P.L. Li, N. Li, Podocyte injury and glomerulosclerosis in hyperhomocysteinemic rats, *Am. J. Nephrol.* 27 (2007) 262–268, <https://doi.org/10.1159/000101471>.
- [260] Y. Long, J. Nie, Homocysteine in renal injury, *Kidney Dis. (Basel, Switzerland)* 2 (2016) 80–87, <https://doi.org/10.1159/00044900 PM - 27536696 M4 - Citavi>.
- [261] G. Stojan, W. Fu, M. Petri, Homocysteine, antiphospholipid antibodies and risk of vascular events in patients with systemic lupus erythematosus [Abstract], *Ann. Rheum. Dis.* 76 (2017).
- [262] S.C. Ross, P. Densen, Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency, *Medicine (Baltimore)* 63 (1984) 243–273 <http://www.ncbi.nlm.nih.gov/pubmed/6433145>.
- [263] A. Danza, G. Ruiz-Irastorza, Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies, *Lupus* 22 (2013) 1286–1294, <https://doi.org/10.1177/0961203313493032>.
- [264] L. Carli, C. Tani, V. Spera, R. Vagelli, S. Vagnani, M. Mazzantini, O. Di Munno, M. Mosca, Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus, *Lupus Sci. Med.* 3 (2016) e000098, <https://doi.org/10.1136/lupus-2015-000098>.
- [265] C. Edens, A.B. Robinson, Systemic lupus erythematosus, bone health, and osteoporosis, *Curr. Opin. Endocrinol. Diabetes Obes.* 22 (2015) 422–431, <https://doi.org/10.1097/MED.0000000000000197>.
- [266] V.Z.C. Borba, P.G. Matos, P.R. Da Silva Viana, A. Fernandes, E.I. Sato, M. Lazaretti-Castro, High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients, *Lupus* 14 (2005) 529–533, <https://doi.org/10.1191/0961203305lu21540a>.
- [267] L. Buckley, G. Guyatt, H.A. Fink, M. Cannon, J. Grossman, K.E. Hansen, M.B. Humphrey, N.E. Lane, M. Magrey, M. Miller, L. Morrison, M. Rao, A.B. Robinson, S. Saha, S. Wolver, R.R. Bannuru, E. Vaysbrot, M. Osani, M. Turgunbaev, A.S. Miller, T. McAlindon, 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis, *Arthr. Rheumatol.* 69 (2017) 1521–1537, <https://doi.org/10.1002/art.40137>.
- [268] J.J.B. Anderson, B. Kruszka, J.A.C. Delaney, K. He, G.L. Burke, A. Alonso, D.E. Bild, M. Budoff, E.D. Michos, Calcium intake from diet and supplements and the risk of coronary artery calcification and its progression among older adults: 10-year follow-up of the multi-ethnic study of atherosclerosis (MESA), *J. Am. Heart Assoc.* 5 (2016) 1–13, <https://doi.org/10.1161/JAHA.116.003815>.
- [269] E. Der, S. Ranabothu, H. Suryawanshi, K.M. Akat, R. Clancy, P. Morozov, M. Kustagi, M. Czuppa, P. Izmirly, H.M. Belmont, T. Wang, N. Jordan, N. Bornkamp, J. Nwaukoni, J. Martínez, B. Gollav, J.P. Buyon, T. Tuschl, C. Putterman, Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis, *JCI Insight* 2 (2017), <https://doi.org/10.1172/jci.insight.93009>.